

The Institute of Cancer Research: Royal Cancer Hospital

Annual Report and Financial Statements
2010

Company Number 534147

The Institute of Cancer Research: Royal Cancer Hospital

Company Number 534147

Financial Statements for the year ended 31 July 2010

CONTENTS	Page Number
Report of the Board of Trustees	2-15
Independent Auditors' Report	16-17
Consolidated Income & Expenditure Account	18
Statement of Total Recognised Gains & Losses	19
Balance Sheets	20
Consolidated Cash Flow Statement	21
Notes to the Consolidated Cash Flow Statement	22
Notes to the Financial Statements	23-44
Strategic Plan	45-64
Governing Committees, Fellows, Members, and Associates of the Institute of Cancer Research	65-70
Legal and Administrative Details	71

REPORT OF THE BOARD OF TRUSTEES FOR THE YEAR ENDED 31 JULY 2010

The Board of Trustees of the Institute of Cancer Research ('the ICR') present their Annual Report and Financial Statements for the year ended 31 July 2010.

1. ACCOUNTING POLICIES

The ICR follows accounting policies contained in the Statement of Recommended Practice 'Accounting for further and higher education' issued in October 2007. The accounts consolidate the activities of the ICR's subsidiaries ICR Sutton Developments Limited and ICR Chelsea Developments Limited which undertake construction work for the ICR, ICR Enterprises Limited which carries out the ICR's trading activities and ICR Equipment Leasing No.8 which holds a lease over one of the ICR's properties. None of these companies had any external activities.

2. PUBLIC BENEFIT

The ICR has complied with the duty in Section 4 of the Charities Act 2006 to have due regard to public benefit guidance published by the Charity Commission.

The ICR was established in 1909. The exclusively charitable objects of the ICR are the study of disease and particularly the disease of cancer and allied diseases; to initiate, encourage, support and carry out research into the causes, prevention, diagnosis and methods of treatment of such diseases; to assist in the prevention, diagnosis and treatment of such diseases, and to provide for the education and practical training in subjects relevant to the study of cancer and allied diseases and the alleviation of suffering.

All that the ICR undertakes relates to research and education for the public benefit and not for profit. The ICR's Strategic Plan for 2010 to 2015 can be found on pages 45-64. This details the ICR's current objectives and highlights the achievements made in the last year towards those objectives.

3. CORPORATE GOVERNANCE

The Institute of Cancer Research together with The Royal Marsden NHS Foundation Trust forms the largest comprehensive cancer centre in Europe, and one of the leading centres in the world. The ICR has authorised a total of 1176 posts. During the year the ICR had an average of 1096 employees of whom 91% (2009: 91%) are directly engaged in research and research support. It raised £83.9 million (2009: £83.8 million) during the year from research grants and voluntary income and spent some £80.5 million (2009: £86.9 million). Capital expenditure was £5.4 million (2009: £8.1 million).

The ICR is

- a research enterprise
- a higher education institution
- a company limited by guarantee
- an exempt charity

The ICR's objects, powers and framework of governance are set out in its

Memorandum and Articles of Association, the current version of which was approved by the Members of the ICR in March 2005.

The overall governing body of the ICR is its Board of Trustees.

The Board of Trustees (Chaired by Lord Ryder of Wensum)

As a charity the ICR is governed by charity trustees collectively known as the Board of Trustees. The trustees carry the responsibility of company directors of the ICR. The Board of Trustees comprises 24 individuals nominated by The University of London, The Royal Marsden NHS Foundation Trust, Cancer Research UK; individuals co-opted by the Board of Trustees itself and others elected by the Academic Board, together with ex-officio members (the Chief Executive and the Academic Dean) and a student nominee.

The Board of Trustees carries the overall responsibility for ensuring that the ICR pursues its charitable objects, complies with its own constitution and relevant legislation and regulations, applies its resources exclusively to its objects and enacts cancer research of the highest international standard. The Board endeavours to conduct its business in accordance with the seven principles identified by the Committee on Standards in Public Life (selflessness, integrity, objectivity, accountability, openness, honesty and leadership). In addition, the Board of Trustees recognises the principles underlying 'The Committee on Corporate Governance's Combined Code' and The Committee of University Chairmen Governance Code of Practice and applies them within the ICR.

The Board of Trustees determines the ICR's strategies; approves its scientific and financial plans, annual report and accounts and governance structure, makes key appointments (Chief Executive, Secretary of the Institute, Academic Dean) and monitors the ICR's strategic performance. It also approves new initiatives and non-recurrent expenditure costing £500,000 or more.

To aid Board members' understanding of the ICR's research priorities, scientific presentations are given at Board meetings.

During the financial year the ICR welcomed Professor Adrian Harris, Miss Kathrin Heinzmann, Lady Helen Otton and Professor Andrew Pearson to its governing body.

During the financial year Miss Rachel Bibby and Mr Dermot Glesson stepped down from the governing body. The ICR is grateful for their valuable contributions during their appointments. Mrs Tessa Green has stepped down since 1 August 2010.

The Board of Trustees met six times in 2009/10. During the year the Board undertook a review of its own performance and that of the sub-committees that report to the Board. No major areas of concern arose from the review. The Board received an annual report relating to Key Performance Indicators. The vast majority of research, as judged by international peer review, is rated as of international standard and in the opinion of the Board of Trustees satisfactory progress is being made towards the ICR's long-term goals.

To facilitate the smooth running of the ICR, the Board of Trustees has established a

number of sub-committees. The terms of reference of each committee have been approved by the Board of Trustees.

The Academic Board (Chaired by Professor Alan Horwich)

The Academic Board meets three times a year and advises, through the Academic Dean, the Board of Trustees on all academic and teaching matters and questions of education policy, and ensures that the ICR, as a College of the University of London, has a rigorous and responsive Quality Assurance framework in place. It is responsible for matters relating to quality assurance and enhancement procedures and academic standards.

The Audit Committee (Chaired by Mr John Pearce)

The Audit Committee meets at least four times a year. The Committee supervises internal and external audit in order to safeguard the integrity of the ICR's financial systems and ensure economy, efficiency and effectiveness in the use of the ICR's resources. Meetings are usually attended by senior members of the ICR's external auditors and the ICR's Chief of Internal Audit Services. The Committee has full access to the internal and external auditors who in turn have access at all times to the Chairman of the Audit Committee.

The Constitutional and Nomination Committee (Chaired by Lord Ryder of Wensum)

The Constitutional and Nomination Committee meets at least twice a year and approves the balance of skills and attributes required of non-executive members of ICR committees so that the ICR may be properly and independently governed. The Committee appoints such individuals to fulfil that function (except to the Board of Trustees) and appoints Associates of the ICR. The Committee recommends to the Board of Trustees the admission of Fellows and Members of the ICR and appointments to the Board of Trustees.

When considering new appointments the Constitutional and Nomination Committee seeks proposals for candidates from a number of sources. During 2009/10 four new appointments were made to the Board of Trustees. All new Trustees are offered a tailored induction programme.

The appointment of Professor Pearson (Academic Board) and Miss Heinzmann (student) were to elected positions. The appointments of Professor Harris and Lady Otton were made following internal and external consultation relating to appointments in areas of expertise that the Board would benefit from.

The Remuneration Committee (Chaired by Lord Ryder of Wensum)

The Remuneration Committee meets at least once a year. The Committee determines the remuneration policy and the salaries of senior members of staff. A Report from the Remuneration Committee is set out on pages 8-10.

The Corporate Management Group (Chaired by Professor Peter Rigby)

The Corporate Management Group meets every three or four weeks to assist the Chief Executive in managing the ICR to achieve its strategic aim and objectives within the approved strategy for research and education, and within the approved budget.

The Joint Research Committee (Chaired by Professor Christopher Marshall)

The Joint Research Committee meets six times a year. The Committee advises the Chief Executives and through them, the ICR's Board of Trustees and The Royal Marsden NHS Foundation Trust's Board of Directors on all research strategies and priorities.

The Investments and Building Development Committee (Chaired by Konstantin Graf von Schweinitz)

The Investments and Building Development Committee meets four times a year. The Committee manages the ICR's investments and building developments.

Declaration of Interests

The Board of Trustees has adopted the following policy on the 'Registration and Declaration of Interests':

- (1) All Board and committee members should declare any interests which may potentially cause a conflict in the course of fulfilling their duties and responsibilities as a Board or committee member.
- (2) Charities should work together for the public good and the betterment of cancer research. Cross trusteeship and committee membership between cancer charities should be seen as complementary and beneficial providing such trusteeship or committee membership is properly exercised.
- (3) Individuals who are a trustee or an employee of more than one charity or a director of a business will have to recognise that there may be occasions when, for example, joint ventures between such organisations require legal agreements or financial arrangements to be negotiated. On such occasions the individual will need to decide which organisation has his/her predominant allegiance and participate only in the discussion and decision of that organisation. Where the ICR is not the individual's predominant allegiance, the individual non-executive member will normally be expected to withdraw from the ICR meeting. Such withdrawal could, exceptionally, be waived at the Committee's discretion. Such interests, when declared, withdrawal or waiver thereof, will be recorded in the minutes.

A copy of the Register of Interests of Board members is available upon application to the Secretary of the ICR.

4. RESEARCH REVIEW

Some 91% (2009: 89%) of the ICR's activities are funded from competitively won peer-reviewed grants or through the competitive Research Assessment Exercise of the Higher Education Funding Council for England, which measures research excellence. These mechanisms ensure the timely external review of all the ICR's research activities. Our ability to prosecute such research depends on our ability to win funds to do so.

5. INTERNAL CONTROL

The ICR is committed to following best practice in all aspects of corporate governance. The summary describes how the ICR has applied the principles set out

in Section 1 of the Combined Code on Corporate Governance issued by the London Stock Exchange in June 1998 and parts 1 and 2 of the Committee of University Chair's Guide for Members of Higher Education Governing Bodies in the UK issued in March 2009.

The Board of Trustees is responsible for the maintenance of a system of internal control which provides reasonable assurance that risks to the achievement of policies, aims and objectives are being satisfactorily managed, assets of the ICR are safeguarded, transactions are properly authorised, financial statements are prepared from reliable records and the requirements of applicable laws and regulations are met.

The ICR's financial affairs are overseen by the following sub-committees of the Board of Trustees - the Audit Committee, the Remuneration Committee and the Investments and Building Development Committee.

The Board of Trustees has designated the Chief Executive as its Accountable Officer and the Designated Office Holder for Higher Education Funding Council for England (HEFCE) purposes and has designated the Secretary of the ICR as its Principal Financial Officer. The Chief Executive is responsible to the Board of Trustees for managing the ICR within the approved budget and recommending the allocation of resources; the Secretary of the ICR is responsible for recommending the resources which are available for allocation.

The system of internal control is risk-based and encompasses a number of elements that facilitate an effective and efficient operation, enabling the ICR to respond to a variety of risks. These are described below.

a. Risk Management

The Corporate Management Group and Corporate Service Directors, assisted by the individual responsible for the risk, are responsible for the identification and management of all the major risks to achievement of the ICR's strategic objectives. This review covers all risks including financial, business, operational and compliance risks. Each risk identified by the Group is assessed and prioritised with reference to the potential impact if the risk occurred and the likelihood of occurrence. The responsibility for specific risks is assigned to the relevant academic, scientific and support staff who provide assurance of the action taken.

The Risk Register is compiled by the Corporate Management Group and approved annually by the Board of Trustees. Significant risks may be added, revised or removed from the Risk Register after evaluation by the Corporate Management Group throughout the year.

The High Impact Risk List is abstracted from the Risk Register and compiled by the Corporate Management Group. It helps to facilitate the identification, assessment and ongoing monitoring of key risks significant to the ICR. Emerging key risks are added and improvement actions implemented as required also throughout the year.

The High Impact Risk List is appraised every four months by the Corporate Management Group and the Board of Trustees.

b. Policies and Procedures

The ICR has a series of policies set by the Board of Trustees that have regard to risks and underpin the internal control process. Written procedures support the policies where appropriate.

c. Financial Controls

In managing its affairs, the ICR has put in place strict authorisation, approval and control levels within which staff operate. The ICR's financial controls are organised as follows:

- (i) The Financial Strategy is approved by the Board of Trustees
- (ii) The Standing Financial Instructions are approved by the Board of Trustees
- (iii) The Financial Regulations are approved by the Corporate Management Group
- (iv) Financial Procedures are approved by the Secretary, as Principal Financial Officer, and/or the Director of Finance.

The overall budget of the ICR is approved by the Board of Trustees. The Board of Trustees has reserved to itself the requirement to authorise any proposal costing £500,000 or more and has set in place authorisation levels for operation by the ICR's staff for expenditure below this level.

d. Planning

A planning process is used to set objectives, agree action plans and allocate resources. Risk identification is integrated into the planning process and risk reporting into regular review of progress against plans.

e. External Consultants

External Consultants are used as necessary to report on specialist areas such as Health and Safety or Information Technology and provide advice on actions required to achieve improvements.

f. Internal Audit

Internal Audit adopts a risk based approach undertaking a programme of examinations covering all aspects of the ICR's activities and provides to the Board of Trustees and the Chief Executive an independent annual statement on the adequacy and effectiveness of risk management, control and governance and arrangements for economy, efficiency and effectiveness and the extent to which the Board of Trustees can rely on these.

In undertaking its work, Internal Audit has regard to Annexes A and B of the Model Financial Memorandum between HEFCE and Institutions, and engagements are conducted in conformance with the International Standards for the Professional Practice of Internal Auditing. The Chief of Internal Audit Services ultimately has the right of direct access to the Chairman of the Board of Trustees, the Chief Executive and the Chairman of the Audit Committee.

Internal Audit's independence is safeguarded by virtue of its direct reporting line to the Audit Committee. It is not directly responsible to any ICR officer other than to the Secretary in respect of general administration and guidance in day-to-day matters.

Once a year the Audit Committee meets with the Chief of Internal Audit Services and representatives of the External Auditors without any ICR officers present. Throughout the year Internal Audit had access to all areas of the ICR and its records.

g. External Audit

The External Auditors provide feedback to the Audit Committee on the operation of internal financial controls reviewed as part of the external audit and include within their audit procedures the monitoring of the ICR's management of risk.

h. Audit Committee

The Audit Committee, on behalf of the Board of Trustees, keeps under review the adequacy and effectiveness of the ICR's arrangements for risk management, control and governance throughout the year, and for the management and quality assurance of data submitted to HESA, HEFCE and other funding bodies, through assessment of the work undertaken by Internal and External Audit, including consideration of all reports from the auditors and other working groups, and through them the management of the ICR. This review also covers compliance with laws and regulations and the economy, efficiency and effectiveness of operations. The Audit Committee reviews the ICR's arrangements for the management of risks, including use of the self assessment checklist for Audit Committees contained in HEFCE's Good Practice Guidance for risk management in higher education.

The Audit Committee's opinion is that the ICR has adequate and effective arrangements for:

- risk management, control and governance; and
- economy, efficiency and effectiveness

and that the Board of Trustees can place reliance on those arrangements. Its opinion regarding the adequacy and effectiveness of the arrangements for the management and quality assurance of data provided to HEFCE, HESA and other public bodies, is that remaining areas of weakness are being dealt with and overall they are effective.

Conclusion

The Board of Trustees is of the view that there is an ongoing process for identifying, evaluating and managing the ICR's key risks, and that it has been in place for the year ended 31 July 2010 and up to the date of the approval of the annual report and accounts, that it is regularly reviewed by the Board of Trustees and that it accords with the internal control guidance for directors in the Combined Code as deemed appropriate for higher education.

6. REPORT OF THE REMUNERATION COMMITTEE

Remit of the Remuneration Committee

The Remuneration Committee comprises four Members of the ICR. Appointments are such that between them, the members of the Remuneration Committee have expertise in the management of medical/biomedical research, the commercial sector, the public sector and any other areas, as the Committee deems necessary. The current membership comprises the ICR's Chairman, who chairs the Committee, the Deputy Chairman of the ICR, the Honorary Treasurer and one other co-opted member of the Board of Trustees.

The Committee determines, on behalf of the Board of Trustees, all matters concerning the terms and conditions and remuneration packages (including pension benefits and severance payments, if any, but see also below) of the Executive Directors of the ICR (the Chief Executive, the Secretary of the Institute, the Academic Dean) and other senior staff (the Chairmen of the research sections, Professors and the Directors of Corporate Service functions).

The Chief Executive is a non-executive director of The Royal Marsden NHS Foundation Trust. The remuneration received from this post is donated to the ICR.

Remuneration Policy

It is the aim of the ICR's Human Resource Strategy to provide a framework within which the ICR may direct and develop staff to realise their full potential to enact cancer research of the highest international standards.

To that end it is an objective of the strategy to create a climate where the ICR can recruit, retain and motivate the best staff to further its research aims and objectives by enabling the ICR to:

- compete effectively in the market place;
- encourage innovation and improve performance;
- develop the research leaders of tomorrow;
- identify and reward excellence.

Within this aim and objective it is current practice to:

- have regard to market pay rates;
- recognise achievement financially.

The Committee has therefore determined a pay policy for senior staff which takes account of the following factors:-

1. Individual performance assessed by reference to:
 - the responsibilities of the individual post;
 - the management and performance of the research section/team or service for which the individual is responsible;
 - the individual's contribution to the ICR's overall performance.
2. Individual remuneration determined by reference to:
 - pay awards agreed for other staff within the ICR;
 - sustained exceptional performance which may be rewarded by increases in basic pay (ie permanent additions);
 - exceptional contributions in a particular year which may be rewarded by one-off bonuses;
 - the need to recruit and retain rare skills and abilities, both nationally and internationally;
 - the strategic needs of the organisation.
3. Comparison with other relevant organisations.

Disciplinary Action

In the event that the ICR is considering disciplinary action against a member of staff whose remuneration falls within the remit of the Remuneration Committee, the

Committee has determined that the ICR should make no financial commitment relating to the departure of the member of staff before completing the necessary disciplinary action.

The remuneration of the Executive Officers and other senior staff is disclosed in Note 17 of the Annual Accounts.

7. OVERALL RESULTS

The full accounts are reproduced on pages 18 to 44.

The ICR's principal activities are research into the causes, prevention, diagnosis and methods of treatment of cancer and the education and advanced training of medical and scientific staff. There have not been any significant changes in the ICR's principal activities in the year under review.

Income for 2010 was £83.9 million compared to £83.8 million. Income from research grants and contracts increased by £1.4 million to £49.8 million and academic fees and support grants also increased. However, these increases were offset by reduced investment income (£1.0 million compared to £2.0 million), lower Funding Council grant income (£24.1 million compared to £24.6 million) and a small fall in other operating income (£7.7 million compared to £7.8 million).

The accounts show a surplus of £3.3 million (2009: deficit of £3.1 million). This surplus includes a £5 million pension credit arising on the change from using the Retail Prices Index to the Consumer Prices Index for the revaluation of pension benefits.

8. EXPENDITURE

Total expenditure was £80.5 million (2009: £86.9 million). This reduction includes a £5 million pension credit arising on the change from using the Retail Prices Index to the Consumer Prices Index for the revaluation of pension benefits, which reduces staff costs in the year. Excluding this pension credit, expenditure in 2010 was 1.6 per cent lower than in 2009.

9. VOLUNTARY INCOME

Legacy income fell in 2010 by £1.3 million to £3.0 million. Donations rose to £2.9 million from £2.6 million, in particular due to increased income from trusts and major donors. The Institute is participating in the Matched Funding initiative of the Higher Education Funding Council for England which covers the three years from 1 August 2008 to 31 July 2011. The additional HEFCE grant income arising from the matching of donations in 2010 was £0.9 million.

10. CAPITAL DEVELOPMENTS

As a result of the difficult economic environment and reduced income expectations in the near term, the completion of the development of our multi-modality imaging centre in the second phase of the Sir Richard Doll Building has been postponed until economic conditions improve and further funding becomes available. Capital expenditure in 2010 was directed to investment in scientific infrastructure and equipment necessary for the advancement of the research strategy of The Institute.

11. REVALUATION OF PROPERTY FIXED ASSETS

The ICR's accounting policy is to revalue its scientific properties. A full revaluation was carried out as at 31 July 2010 on a depreciated replacement cost basis and the ICR's properties were revalued at £77.9 million.

12. RESERVES POLICY

Approximately sixty per cent of the ICR's work is financed from competitively won grants for specific research projects and programmes, thirty per cent from competitively won research funding resulting from the Higher Education Funding Councils' Research Assessment Exercise and the remainder from the ICR's voluntary and investment income.

The ICR's mission is a long-term undertaking and whilst the Board of Trustees of the ICR expends all the funds it receives towards its mission within a reasonable time of receiving them, it also considers it is prudent to maintain a reserve of free funds to assure the long-term financial viability of the ICR's work. Free funds are expendable at the Board of Trustees' discretion and not designated for a particular purpose.

In determining the level of free funds to be held in reserve the Board of Trustees considers the ICR's future needs and possible risks. In particular the Board of Trustees considers, having designated funds for particular research and infrastructure needs (if to be financed from reserves) and for capital developments, and in accordance with Charity Commission guidance:

- the forecast for levels of income in future years, taking into account the reliability of each source of income and the prospects for opening up new sources
- the forecasts of expenditure in future years on the basis of planned activity
- its analysis of any future needs, opportunities, contingencies or risks the effects of which are not likely to be met out of income if and when they arise
- its assessment, on the best evidence available, of the likelihood of each of these needs, opportunities, contingencies or risks arising and the consequences for the ICR of not being able to meet them.

The Board of Trustees reviews this policy and the assessment and calculation of the level of free reserves each year.

13. INVESTMENT POLICY AND PERFORMANCE

Under the Memorandum and Articles of Association the ICR can "invest and deal with any monies not immediately required for its purposes in such a manner as may be thought fit". The ICR does not invest directly in any company perceptibly involved in the sale of tobacco or tobacco products. The exercise of the investment powers is the responsibility of the Investments and Building Development Committee.

The aim of the Investment Policy is to maintain a balance between current income and capital growth commensurate with the ICR's liquidity requirements. The asset distribution is subject to review at regular Investments and Building Development Committee meetings and is dependent on the ICR's programme for future development.

During the year the Institute appointed new investment managers, Partners Capital

LLP, and adopted a new investment policy which broadened the asset classes available for investment and the diversification of the investment portfolio. Derivative investments are used only for the purposes of managing risk related to foreign currency exposures and not for speculation. A gain on investments of £0.9 million is reported in the statement of total recognized gains and losses.

14. PENSIONS

The last actuarial valuation of the ICR Pension Scheme was undertaken as at 31 March 2007 and this showed that the scheme deficit had deteriorated from £8.7 million as at 31 March 2004 to a deficit of £12.7 million at 31 July 2007. The actuarial valuation of the Scheme as at 31 March 2010 is currently being finalised.

The ICR Pension Scheme closed to future accrual on 31 July 2008 and active members were able to build future pension within the Universities Superannuation Scheme after that date.

In common with many other defined benefit pension schemes, the funding position of the Scheme has deteriorated throughout the last year. The financial statements show that the Scheme is in deficit by £11.7 million on an FRS17 basis at 31 July 2010. However, the ICR has been advised that a scheme valuation on a funding basis, rather than FRS17, would show the Scheme to be in deficit by approximately £13.5 million as at 31 July 2010. The Trustees continue to review the options with regard to the future of the closed scheme and how best to secure the funding position.

On 8 July 2010, the Minister for Pensions announced the government's intention to move to using the Consumer Prices Index (CPI) rather than the Retail Prices Index (RPI) as the inflation measure to use in determining the minimum pension increases to be applied to the statutory index-linked features of retirement benefits. As a result of this change, a non-cash reduction in past service pension costs of £5.0 million arose in the year.

The reported scheme liabilities also include an allowance of approximately £6.9 million for discretionary pension increases which may be made in future for pensions in payment where no index-linking is provided for under the Scheme Rules. The Board of Trustees decides annually whether discretionary payments should be made. No discretionary increases were approved in the financial year, in line with the underlying downward movement in inflation indices.

15. RISKS

The principal risks facing the ICR concern the security of its funding streams. The funding from HEFCE is dependent on the ICR maintaining the high quality of its research activity and, also, the resources available for distribution to the sector by the Funding Council. The income from external grant funders is dependent on the continued success of ICR scientists in securing funding for its projects in competitive peer reviewed programmes and the resources grant giving charities have available. The ICR seeks to limit this risk by diversifying its sources of funding and retaining reserves to address funding fluctuations.

The ICR operates a defined benefit pension scheme now closed to future accrual and is exposed to movements in its assets and liabilities. The ICR seeks to limit these

risks by seeking ways to manage down the size of the scheme liabilities and adopting a diversified investment strategy.

16. EMPLOYEES

Disabled employees:

The ICR recognises its obligations to disabled persons. In accordance with the provisions of the Disability Discrimination Act 1995, the ICR endeavours to provide equality in recruitment, training, career development, working conditions and dismissal as the demands of its research work and the ability of each individual allows.

Employee involvement:

The ICR uses a number of methods to keep its staff fully informed of matters of concern to them. These include four-monthly briefings by the Chief Executive of all staff, Board of Trustees' minutes, summaries of Corporate Management Group meetings and regular organisational updates which are distributed by e-mail and displayed throughout the ICR.

Formal communications with staff take place through four-monthly meetings of the Staff Consultative Committee. This consists of an equal number of representatives of the staff and management and is chaired by the Director of Human Resources. It is ICR policy to promote by discussion and consultation the involvement of staff, when appropriate, in the development of personnel policy and practice.

17. CHARITABLE AND POLITICAL DONATIONS

The ICR made no charitable or political donations during the current and previous year.

18. COMPANY NUMBER

The Company Registration Number is 534147.

19. AUDITORS

On 1 October 2010, Horwath Clark Whitehill LLP changed its name to Crowe Clark Whitehill LLP. Crowe Clark Whitehill LLP has indicated its willingness to be reappointed as statutory auditor.

Non-audit services

From time to time it is necessary to employ the ICR's external auditors for certain non-audit work. In order to maintain the independence of the external auditors, the Audit Committee has determined policies as to what non-audit services can be provided by the ICR's external auditors. The Audit Committee monitors the level of non-audit fees paid to the external auditors. No non-audit fees were paid to the external auditors in 2010 or 2009.

Provision of information to auditors

Each of the persons who is a trustee at the date of approval of this report confirms that:

- so far as the Board of Trustees are aware, there is no relevant audit information of which the ICR's auditors are unaware; and

- the Board of Trustees has taken all the steps that they ought to have taken as directors in order to make themselves aware of any relevant audit information and to establish that the ICR's auditors are aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of Section 418 of the Companies Act 2006.

20. STATEMENT OF THE FINANCIAL RESPONSIBILITIES OF MEMBERS OF THE BOARD OF TRUSTEES

The Institute of Cancer Research is a company limited by guarantee, a College of the University of London, and an exempt charity under the Second Schedule of the Charities Act 1993. Members of the Board of Trustees, the governing body of the ICR, are therefore both its company directors and charity trustees.

The Trustees are responsible for preparing the Report of the Board of Trustees and the financial statements in accordance with applicable law and regulations.

Company law requires the Trustees to prepare financial statements for each financial year. Under that law the Trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards) and applicable law.

Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the financial position of ICR for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the ICR will continue in business.


The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the ICR's transactions and disclose with reasonable accuracy at any time the financial position of the ICR and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the ICR and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

21. GOING CONCERN

The Board of Trustees has considered the level of reserves and the financial resources available to the ICR and considers that these are adequate to meet its operational needs for the foreseeable future. Consequently the going concern basis has been adopted in preparing these Financial Statements.

22. APPROVAL OF THE FINANCIAL STATEMENTS

The Financial Statements were approved by the Board of Trustees on 18 November 2010.

A handwritten signature in black ink, appearing to read 'Lord Ryder'.

Lord Ryder of Wensum
Chairman of The Institute of Cancer Research

INDEPENDENT AUDITORS' REPORT TO THE GOVERNING BODY OF THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

We have audited the financial statements of The Institute of Cancer Research: Royal Cancer Hospital for the year ended 31 July 2010 which comprises the consolidated income and expenditure account, the balance sheets, the consolidated cash flow statement, the reconciliation of net cash flow to movement in net funds, the statement of total recognised gains and losses, the statement of historical cost surplus, the statement of accounting policies and the related notes 1 to 24. These financial statements have been prepared under the accounting policies set out therein.

This report is made solely to the Board of Trustees of the Institute, as a body, in accordance with the Financial Memorandum dated July 2010. Our audit work has been undertaken so that we might state to the Board of Trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Board and the Board's members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of Governing Body and auditors

As described in the statement of the Board of Trustees' responsibilities, the Board is responsible for the preparation of the financial statements in accordance with the University's statute, the Statement of Recommended Practice on Accounting for Further and Higher Education and other applicable United Kingdom law and accounting standards (United Kingdom Generally Accepted Accounting Practice).

Our responsibility is to audit the financial statements in accordance with relevant United Kingdom legal and regulatory requirements and International Standards on Auditing (UK & Ireland).

We report to you our opinion as to whether the financial statements give a true and fair view and are properly prepared in accordance with the Statement of Recommended Practice on Accounting for Further and Higher Education. We also report whether income from funding bodies, grants and income for specific purposes and from other restricted funds administered by the Institute of Cancer Research have been properly applied only for the purposes for which they were received and whether income has been applied in accordance with the Statutes and, where appropriate, with the Financial Memorandum with the Higher Education Funding Council for England.

We also report if, in our opinion, the Board of Trustees' report is not consistent with the financial statements, if the Group has not kept proper accounting records, the accounting records do not agree with the financial statements or if we have not received all the information and explanations we require for our audit.

We read the other information contained in the Board of Trustees' report, and consider the implications for our report if we become aware of any apparent misstatements or material inconsistencies with the financial statements.

Basis of opinion


We conducted our audit in accordance with International Standards issued by the Auditing Practices Board and the Audit Code of Practice issued by the Higher Education Funding Council for England. An audit includes examination, on a test basis, of evidence relevant to the amounts and estimates and judgements made by the Trustees in the preparation of the financial statements and of whether the accounting policies are appropriate to the group's circumstances, consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion we also evaluated the overall adequacy of the presentation of information in the financial statements.

Opinion

In our opinion:

- the financial statements give a true and fair view of the state of affairs of the Institution and the group as at 31 July 2010 and of the group's result for the year then ended and have been properly prepared in accordance with the Statement of Recommended Practice on Accounting for Further and Higher Education;
- in all material respects the income received from the Higher Education Funding Council for England, grants and income for specific purposes and from other restricted funds administered by the Institute have been applied only for the purposes for which they were received; and
- in all material respects income has been applied in accordance with the Institute's statutes and, where appropriate, with the financial Memorandum, dated July 2010 with the Higher Education Funding Council for England.



Pesh Framjee
Senior Statutory Auditor
for and on behalf of
Crowe Clark Whitehill LLP
Chartered Accountants
Statutory Auditor
St Bride's House
10 Salisbury Square
London EC4Y 8EH, UK

23 November 2010

THE INSTITUTE OF CANCER RESEARCH**CONSOLIDATED INCOME AND EXPENDITURE ACCOUNT**
for the year ended 31 July 2010

	Note	2010 £000	2009 £000
Income			
Funding Council grants	2	24,112	24,578
Academic fees and support grants	3	1,232	1,091
Research grants and contracts	4	49,814	48,386
Other operating income	5	7,685	7,787
Endowment and investment income	6	1,017	1,959
Total income		<u>83,860</u>	<u>83,801</u>
Expenditure			
Staff costs	19	46,282	48,494
Other operating expenses	7	30,024	33,251
Depreciation	8	4,223	5,187
Total expenditure		<u>80,529</u>	<u>86,932</u>
Surplus/(deficit) on continuing operations after depreciation of fixed assets at valuation and before and after tax		<u>3,331</u>	<u>(3,131)</u>

All the Institute's operations are continuing.

The notes on pages 23 to 44 form part of these financial statements.

THE INSTITUTE OF CANCER RESEARCH**STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES**
for the year ended 31 July 2010

	2010	2009
Note	£000	£000
Recognised losses relating to the year		
Surplus/(deficit) on continuing operations after depreciation of assets at valuation, disposal of assets and tax	3,331	(3,131)
Unrealised deficit on revaluation of fixed assets	(3,809)	-
Appreciation/(depreciation) of investments	907	(241)
Actuarial loss on defined benefit pension schemes	19 (8,354)	(7,076)
Total recognised losses relating to the year	<u>(7,925)</u>	<u>(10,448)</u>
Reconciliation		
Opening reserves and endowments	89,655	100,103
Total recognised losses for the year	<u>(7,925)</u>	<u>(10,448)</u>
Closing reserves and endowments	<u>81,730</u>	<u>89,655</u>

STATEMENT OF HISTORICAL COST SURPLUS/(DEFICIT)
for the year ended 31 July 2010

	2010	2009
	£000	£000
Surplus/(deficit) on continuing operations before and after tax	3,331	(3,131)
Difference between historical cost depreciation and the actual charge for the period calculated on the revalued amount	<u>(1,299)</u>	<u>432</u>
Historical cost surplus/(deficit) for the period before and after taxation	<u>2,032</u>	<u>(2,699)</u>

The notes on pages 23 to 44 form part of these financial statements.


THE INSTITUTE OF CANCER RESEARCH


BALANCE SHEETS


31 July 2010

	Note	Group		Institute	
		2010 £000	2009 £000	2010 £000	2009 £000
Fixed assets					
Tangible assets	8	87,830	91,039	87,830	91,039
Investments	9a	45,103	46,049	45,108	46,054
		<u>132,933</u>	<u>137,088</u>	<u>132,938</u>	<u>137,093</u>
Endowment assets	9b	<u>2,527</u>	<u>2,524</u>	<u>2,527</u>	<u>2,524</u>
Current assets					
Stocks - finished goods		254	262	254	262
Investments		5,816	2,200	5,816	2,200
Debtors	10a	10,563	12,331	10,719	12,226
Cash at bank and in hand		1,270	873	1,102	866
		<u>17,903</u>	<u>15,666</u>	<u>17,891</u>	<u>15,554</u>
Creditors: amounts falling due within one year	11a	<u>(19,058)</u>	<u>(19,990)</u>	<u>(19,051)</u>	<u>(19,883)</u>
Net current liabilities		(1,155)	(4,324)	(1,160)	(4,329)
Total assets less current liabilities		134,305	135,288	134,305	135,288
Debtors: amounts falling due after more than one year	10b	628	795	628	795
Creditors: amounts falling due after more than one year	11b	(147)	(147)	(147)	(147)
Provisions for liabilities and charges	11c	(354)	(340)	(354)	(340)
Net assets excluding pension liability		134,432	135,596	134,432	135,596
Defined benefit pension scheme liability	19c	<u>(11,675)</u>	<u>(7,776)</u>	<u>(11,675)</u>	<u>(7,776)</u>
Net assets including pension liability		122,757	127,820	122,757	127,820
Deferred capital grants	12	41,026	38,164	41,026	38,164
Endowments					
Expendable	15	583	820	583	820
Permanent	15	1,944	1,704	1,944	1,704
		<u>2,527</u>	<u>2,524</u>	<u>2,527</u>	<u>2,524</u>
Reserves					
Income and expenditure account excluding pension reserve	13	63,521	63,741	63,521	63,741
Pension reserve	19c	<u>(11,675)</u>	<u>(7,776)</u>	<u>(11,675)</u>	<u>(7,776)</u>
Income and expenditure account including pension reserve		51,846	55,965	51,846	55,965
Revaluation reserve	14	<u>27,358</u>	<u>31,167</u>	<u>27,358</u>	<u>31,167</u>
Total reserves		79,204	87,132	79,204	87,132
Total funds		122,757	127,820	122,757	127,820

These financial statements were approved by the Board of Trustees on 18 November 2010.


Lord Ryder of Wensley
Chairman of the Board of Trustees


Konstantin Graf von Schweinitz
Honorary Treasurer


Paul Norris
Director of Finance

The notes on pages 23 to 44 form part of these financial statements.

THE INSTITUTE OF CANCER RESEARCH**CONSOLIDATED CASH FLOW STATEMENT**
for the year ended 31 July 2010

	Note	2010 £000	2009 £000
Net cash inflow/(outflow) from operating activities	1	371	(3,996)
Returns on investments and servicing of finance	2	1,017	1,959
Capital expenditure and financial investment	3	2,097	(4,054)
Net cash inflow/(outflow) before use of liquid resources and financing		3,485	(6,091)
Financing and management of liquid resources	4	528	5,031
Increase/(decrease) in cash in the year		4,013	(1,060)

ANALYSIS OF NET FUNDS

	1 August 2009 £000	Cash Flows £000	31 July 2010 £000
Cash at bank and in hand	873	397	1,270
Current asset investments	<u>2,200</u>	<u>3,616</u>	<u>5,816</u>
	3,073	4,013	7,086
Money market and other deposits	10,123	(1,528)	8,595
Finance lease	<u>(1,000)</u>	<u>1,000</u>	<u>-</u>
	<u>12,196</u>	<u>3,485</u>	<u>15,681</u>

THE INSTITUTE OF CANCER RESEARCH**NOTES TO THE CONSOLIDATED CASH FLOW STATEMENT**
for the year ended 31 July 2010

1. Reconciliation of consolidated operating surplus to net cash inflow/(outflow) from operating activities

	2010	2009
	£000	£000
Surplus/(deficit) on continuing operations after depreciation of fixed assets at valuation	3,331	(3,131)
Net release of deferred capital grants	(4,312)	(4,881)
Revaluation loss	576	-
Depreciation charges	4,223	5,187
Investment income	(1,017)	(1,959)
Decrease/(increase) in stocks	8	(35)
Decrease/(increase) in debtors	1,935	(4,315)
Increase in creditors	82	5,153
Defined benefit pension scheme settlement gain	(154)	-
Pension contributions less current service and finance costs	743	(15)
Exceptional pension past service credit	(5,044)	-
	371	(3,996)

2. Returns on investments and servicing of finance

	2010	2009
	£000	£000
Income from endowments	28	72
Other investment income	989	1,887
	1,017	1,959

3. Capital expenditure and financial investment

	2010	2009
	£000	£000
Payments to acquire tangible fixed assets	(5,399)	(8,090)
Deferred capital grants received	7,174	8,783
Purchases of investments	(37,450)	(40,425)
Receipts from sales of investments	37,772	35,678
	2,097	(4,054)

4. Financing and management of liquid resources

	2010	2009
	£000	£000
(Decrease)/increase in finance lease	(1,000)	1,000
Decrease in short term deposits	1,528	4,031
	528	5,031

THE INSTITUTE OF CANCER RESEARCH**NOTES TO THE FINANCIAL STATEMENTS**for the year ended 31 July 2010

1. Accounting policies**(i) Basis of preparation**

These financial statements have been prepared in accordance with the Statement of Recommended Practice "Accounting for Further and Higher Education " and annual accounts direction issued by the Higher Education Funding Council for England (HEFCE) issued in July 2010 and in accordance with applicable UK accounting standards.

The financial information set out above does not constitute the company's statutory accounts for the years ended 31 July 2010 or 2009, but is derived from those accounts. Statutory accounts for 2009 have been delivered to the Registrar of Companies and those for 2010 will be delivered following the Institute's annual general meeting. The auditors have reported on those accounts; their reports were unqualified and did not contain statements under s237(2) or (3) Companies Act 1985.

The Trustees consider that The Institute has adequate resources to continue its activities for the foreseeable future and that, for this reason, it should continue to adopt the going concern basis in preparing the accounts.

(ii) Basis of accounting

These financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and investments to market value, in accordance with applicable accounting standards. The Institute has availed itself of Paragraph 3 (3) of Schedule 4 of the Companies Act and adapted the Companies Act formats to reflect the special nature of The Institute's activities.

(iii) Land and buildings

Land and buildings are valued every five years in accordance with the Guidance Notes for the Valuation of Assets issued by the Royal Institute of Chartered Surveyors for the purpose of balance sheet valuations. The last full valuation took place as at 31 July 2010.

Valuations are made on a Depreciated Replacement Cost basis for scientific properties. Unrealised gains arising at each revaluation are shown in the Revaluation Reserve. Unrealised losses are taken to the Income and Expenditure Account, except to the extent that they reverse revaluation gains on the same asset.

Where buildings are acquired and depreciated with the aid of specific grants they are capitalised and depreciated as above. The related grants are treated as Deferred Capital Grants and released to income over the expected useful life of the buildings.

(iv) Investments

Listed investments are stated at their market value at the date of the balance sheet. Unrealised gains and losses arising during the year are included in the Statement of Total Recognised Gains and Losses and are taken to the General Fund.

Investments that are not listed on a recognised stock exchange are carried at their historic cost less any provision for impairment in their value.

(iv) Incoming resources

Income from Research Grants, contracts and other services is included to the extent of the completion of the contract or service concerned. This is generally equivalent to the sum of the relevant expenditure incurred during the year and any related contributions towards overhead costs.

Income from short-term deposits is included in the Income and Expenditure Account in the period in which it is earned.

THE INSTITUTE OF CANCER RESEARCH**NOTES TO THE FINANCIAL STATEMENTS**for the year ended 31 July 2010

1. Accounting policies continued

Recurrent grants from HEFCE are recognised in the period in which they are receivable. Non-recurrent grants from HEFCE or other bodies received in respect of the acquisition or construction of fixed assets are treated as deferred capital grants and amortised in line with depreciation over the life of the asset.

Legacies and donations are included in the Income and Expenditure Account in the year in which they are received except where income is accounted for once it is known with certainty that an identifiable sum of money is going to be received. Entitlement to legacy income is taken to be the earlier of estate accounts being finalised and cash received. This includes the value of material properties which have been bequeathed to The Institute but not realised at the balance sheet date.

(vi) Foreign currency translation

Transactions denominated in foreign currencies are recorded at the rate of exchange ruling at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into sterling either at the year-end rates. The resulting exchange differences are dealt with in the determination of income and expenditure for the financial year.

(vii) Depreciation

Depreciation is provided to write off the costs of leases and buildings over their useful economic lives based on their Net Book Values. The annual rates of depreciation are as follows; -

Freehold buildings 2%

Leasehold buildings 2% or the length of the lease if shorter than 50 years.

The cost of refurbishing and maintaining the buildings is written off in the year the expenditure is incurred.

(viii) Equipment and depreciation

Equipment (including computers and software) and furniture costing less than £25,000 for each individual item are written off in the year of acquisition. All other items of equipment and furniture are capitalised in the year of acquisition. Capitalised equipment is stated at cost and depreciated over four years on a straight - line basis.

(ix) Stocks

Stocks of research material have been valued using the average of opening and closing stock prices.

(x) Pensions

The Institute participates in three defined benefit schemes, the Universities' Superannuation Scheme (USS), National Health Service Pension Scheme (NHSPS) and The Institute of Cancer Research Pension Scheme (ICRPS). USS and NHSPS are multi-employer schemes for which employer contributions are charged directly to the Income and Expenditure Account as if the schemes were defined contribution schemes.

For defined benefit schemes the amounts charged to operating profit are the current service costs and gains and losses on settlements and curtailments. They are included as part of staff costs. Past service costs are recognised immediately in the income and expenditure account if the benefits have vested. If the benefits have not vested immediately, the costs are recognised over the period until vesting occurs. The interest cost and the expected return on assets are shown as a net amount of other finance costs or credits adjacent to interest. Actuarial gains and losses are recognised immediately in the statement of total recognised gains and losses. Defined benefit scheme assets are held separately from those of The Institute. Pension scheme assets are measured at fair value and liabilities are measured on an actuarial basis using the projected unit method and discounted at a rate equivalent to the current rate of return on high quality corporate bonds.

The actuarial valuation is obtained at least tri-annually and is updated at each balance sheet date. The resulting defined benefit asset or liability is shown separately on the face of the balance sheet.

THE INSTITUTE OF CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 July 2010

1. Accounting policies continued

(xi) Consolidation basis

The Institute owns 100% of the share capital of four companies – ICR Enterprise Ltd, ICR Chelsea Development Ltd (ICRCD), ICR Sutton Developments Ltd (ICRSD) and ICR Equipment Leasing No.8 Limited (ICRENO8) ICR Enterprises Ltd undertakes trading activities. ICRCD and ICRSD have been set up to act as developers for the construction of laboratories. ICRENO8 owns a long leasehold interest in the Chester Beatty Laboratory which is occupied by The Institute. The consolidated statements include the financial statements of these companies as well as Everyman Action Against Male Cancer. No Income and Expenditure Account is presented for The Institute.

The Institute makes a small contribution each year towards the costs of the Student Association. The Institute has no management responsibility for the Association and therefore does not consolidate their accounts into The Institute's accounts.

(xii) Leases

Assets held under leasing arrangements which transfer substantially all the risks and rewards of ownership to The Institute are capitalised. The capital element of the related rental obligations is included in creditors. The interest element of the rental obligations is charged to the Income and Expenditure Account so as to produce a constant periodic rate of charge. Other leases are regarded as operating leases and the rentals are charged directly to the Income and Expenditure Account on a straight-line basis over the term of the lease.

(xiii) Research and development

Research and development expenditure is written off in the period in which it is incurred.

THE INSTITUTE OF CANCER RESEARCHNOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 July 2010

2. Funding Council grants

	2010	2009
	£000	£000
<i>Recurrent grants</i>		
Higher Education Funding Council for England (HEFCE)	20,164	20,342
NHS pension funding supplement	187	187
<i>Specific grants</i>		
Higher Education Innovation Fund	402	311
Matched Funding	898	899
Other specific funds	95	16
<i>Deferred capital grants released during the year</i>		
Buildings (note 14)	499	1,704
Equipment (note 14)	1,867	1,119
	24,112	24,578

3. Academic fees and support grants

	2010	2009
	£000	£000
Fees and support grants	1,232	1,091

4. Research grants and contracts

	2010	2009
	£000	£000
UK based charities	34,318	34,782
Research Councils	3,215	4,859
UK Government, local health and hospital authorities	6,496	5,570
EU	1,145	1,006
Industry, commerce and other	3,460	1,124
Other overseas	1,180	1,045
	49,814	48,386

5. Other operating income

	2010	2009
	£000	£000
Legacies and donations	6,014	6,919
Net (receipt)/release of deferred capital grants	763	(238)
Invention and other income	908	1,106
	7,685	7,787

Voluntary income is largely derived from the UK. The Institute has been notified of legacies of £3,169,000 which have not been recognised as income at 31 July 2010 as no notification of impending distribution or approval of estate accounts has been received (2009: £2,843,000).

THE INSTITUTE OF CANCER RESEARCH
NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 July 2010

6. Endowment and investment income

	2010	2009
	£000	£000
Income from permanent endowments	28	72
Other investment income	989	1,887
	<u>1,017</u>	<u>1,959</u>

7. Other operating expenses

	2010	2009
	£000	£000
Laboratory consumables	16,882	18,712
Heat, light, water and power	1,378	1,663
Repairs and general maintenance	4,261	7,200
Rent, rates and insurance	746	748
Other premises	1,661	2,158
Central administration services	903	951
Library and information services	536	451
Information technology	698	347
Other expenses	2,959	1,021
	<u>30,024</u>	<u>33,251</u>

Other operating expenses include the following:

	2010	2009
	£000	£000
Fees payable to the Institute's auditors for the audit of the annual accounts	25	24
The audit of the Institute's subsidiaries, pursuant to legislation	6	6
	<u>31</u>	<u>30</u>
Total external audit fees	31	30
Other service from auditors	-	-
Hire of other assets - operating leases	465	465

THE INSTITUTE OF CANCER RESEARCH
NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 July 2010

8. Tangible assets

Group and Institute

	Freehold land and buildings	Leasehold land and buildings	Furniture plant and equipment - owned	Furniture plant and equipment - leased	Total
	£000	£000	£000	£000	£000
<i>Cost or valuation</i>					
At 1 August 2009	83,837	2,457	18,268	1,000	105,562
Revaluation gain/(loss)	(6,124)	99	-	-	(6,025)
Additions at cost	127	-	5,272	-	5,399
At 31 July 2010	77,840	2,556	23,540	1,000	104,936
<i>Depreciation</i>					
At 1 August 2009	1,618	195	12,460	250	14,523
Revaluation gain/(loss)	(1,608)	(32)	-	-	(1,640)
Provided in the year	-	86	3,887	250	4,223
At 31 July 2010	10	249	16,347	500	17,106
<i>Net book value</i>					
At 31 July 2010	77,830	2,307	7,193	500	87,830
of which:					
Scientific properties	77,780	1,719	-	-	79,499
Other properties	50	588	-	-	638
At 31 July 2009	82,219	2,262	5,808	750	91,039
of which:					
Scientific properties	82,169	1,588	-	-	83,757
Other properties	50	674	-	-	724
<i>Historic cost - net book value</i>					
At 31 July 2010	51,230	1,090	7,193	500	60,013
At 31 July 2009	52,114	1,187	5,808	750	59,859
<i>Financed by</i>					
Capital grant	30,838	214	6,938	500	38,490
Other	46,992	2,093	255	-	49,340
	77,830	2,307	7,193	500	87,830

The net book value of freehold land and buildings includes £1,590,000 in respect of assets under construction (2009: £1,463,000).

The Institute's scientific properties were revalued by Gerald Eve Chartered Surveyors as at 31 July 2010. The valuations were undertaken on a depreciated replacement cost basis. The laboratories were valued at £77.9m. Other properties are included at original cost.

THE INSTITUTE OF CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 July 2010

9. Investments and endowment assets

	Market value 1 Aug 09 £000	Additions at cost £000	Disposals at book value £000	Other move- -ments £000	Gains/ (losses) £000	Market value 31 Jul 10 £000
a. Investments (Group)						
Listed						
UK Government	36,646	4,782	(34,010)	-	(46)	7,372
Other UK	2	4,980	-	-	(3)	4,979
Overseas	-	10,298	(1,210)	-	82	9,170
	<u>36,648</u>	<u>20,060</u>	<u>(35,220)</u>	<u>-</u>	<u>33</u>	21,521
Unlisted						
UK	96	-	-	-	35	131
Overseas	2	14,337	-	-	1,646	15,985
	<u>98</u>	<u>14,337</u>	<u>-</u>	<u>-</u>	<u>1,681</u>	16,116
Derivatives	-	-	-	782	(981)	(199)
Investment cash and deposits	9,303	-	-	(1,548)	(90)	7,665
Total investments	<u>46,049</u>	<u>34,397</u>	<u>(35,220)</u>	<u>(766)</u>	<u>643</u>	45,103
b. Endowment assets (Group and Institute)						
Listed						
UK Government	-	1,773	(1,456)	-	(2)	315
Other UK	1,704	225	(1,929)	-	214	214
Overseas	-	441	(52)	-	4	393
	<u>1,704</u>	<u>2,439</u>	<u>(3,437)</u>	<u>-</u>	<u>216</u>	922
Unlisted						
Overseas	-	614	-	-	70	684
	<u>-</u>	<u>614</u>	<u>-</u>	<u>-</u>	<u>70</u>	684
Derivatives	-	-	-	33	(42)	(9)
Investment cash and deposits	820	-	-	114	(4)	930
Total endowment assets	<u>2,524</u>	<u>3,053</u>	<u>(3,437)</u>	<u>147</u>	<u>240</u>	2,527

The investments held by the Group were all held by The Institute which in addition held investments of £5,000 in subsidiary companies.

The endowment assets are restricted but are managed as part of a single portfolio with the Institute's investments.

Derivatives comprise forward currency contracts which are used for the purpose of risk management rather than speculation in order to translate investment assets denominated in foreign currencies into Sterling and as part of the investment strategy. As at 31 July 2010 the total notional value of open forward contracts amounted to £23,197,000 (2009: £nil).

The historical cost of total investments and endowment assets at 31 July 2010 was £45,783,000 for the Group (2009: £48,640,000) and £45,788,000 (£48,645,000) for The Institute.

THE INSTITUTE OF CANCER RESEARCH

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 July 2010

9. Investments and endowment assets (continued)

The following investments represented holdings in excess of 5% of the investment portfolio at 31 July 2010:

	2010	2009
BlackRock Ascent UK Real Return Bond Fund	5.6%	-
BlackRock GiltTrak Fund	8.3%	-
BlueBay Investment Grade Bond Fund	5.9%	-
BlueBay Investment Grade Libor Fund	5.7%	-
Partners Capital Eagle Fund (C) Ltd	20.2%	-
Partners Capital Falcon Fund (C) Ltd	8.9%	-
Partners Capital Harrier Fund (C) Ltd	8.9%	-
UK Treasury 4.25% 07/03/2011	7.4%	18.3%
UK Treasury 4.50% 07/03/2013	-	18.9%
UK Treasury 4.75% 07/09/2015	-	58.1%

10. Debtors

a. Amounts falling due within one year

	Group		Institute	
	2010	2009	2010	2009
	£000	£000	£000	£000
Revenue grants	2,345	2,371	2,345	2,371
Other trade debtors	269	1,055	236	1,009
Legacy debtors	595	134	595	134
Other debtors	154	299	154	192
Amounts due from subsidiary undertakings	-	-	189	48
Prepayments and accrued income	7,200	8,472	7,200	8,472
	<u>10,563</u>	<u>12,331</u>	<u>10,719</u>	<u>12,226</u>

b. Amounts falling due after more than one year

	Group		Institute	
	2010	2009	2010	2009
	£000	£000	£000	£000
Accrued income	628	795	628	795

THE INSTITUTE OF CANCER RESEARCH
NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 July 2010

11. Creditors

a. Amounts falling due within one year

	Group		Institute	
	2010	2009	2010	2009
	£000	£000	£000	£000
Trade creditors	2,004	3,506	1,999	3,130
Accruals	3,073	2,940	2,973	2,929
Amounts due to subsidiary companies	-	-	98	280
Finance lease creditors	-	1,000	-	1,000
Other creditors	992	1,140	992	1,140
Taxes and social security	1,011	1,010	1,011	1,010
Deferred research grants	11,978	10,394	11,978	10,394
	19,058	19,990	19,051	19,883

b. Amounts falling due after more than one year

	Group		Institute	
	2010	2009	2010	2009
	£000	£000	£000	£000
Other creditors	147	147	147	147

c. Provisions for liabilities and charges

	Group		Institute	
	2010	2009	2010	2009
	£000	£000	£000	£000
<i>Dilapidations and decommissioning</i>				
At 1 August 2009	340	251	340	251
Provided in the year	14	89	14	89
Utilised in the year	-	-	-	-
	354	340	354	340

The dilapidation and decommissioning provision is held to cover liabilities as a result of vacating leasehold premises and the removal of a caesium source.

THE INSTITUTE OF CANCER RESEARCH
NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 July 2010

12. Deferred capital grants

Group and Institute

	HEFCE £000	Other funders £000	Total Total £000
<i>At 1 August 2009</i>			
Land and buildings	17,578	14,616	32,194
Equipment	3,359	2,611	5,970
<i>Cash receivable in the year</i>			
Land and buildings	1,903	-	1,903
Equipment	4,089	1,182	5,271
<i>Released to income and expenditure</i>			
Land and buildings	(499)	(348)	(847)
Equipment	<u>(1,867)</u>	<u>(1,598)</u>	<u>(3,465)</u>
<i>At 31 July 2010</i>			
Land and buildings	18,982	14,268	33,250
Equipment	<u>5,581</u>	<u>2,195</u>	<u>7,776</u>
Total at 31 July 2010	<u>24,563</u>	<u>16,463</u>	<u>41,026</u>

13. Income and expenditure account

	Balance at 1 August 2009 £000	Income £000	Expend- iture £000	Transfers, gains and losses £000	Balance at 31 July 2010 £000
Income and expenditure account excluding pension reserve	63,741	83,860	(80,529)	(3,551)	63,521
Pension deficit	<u>(7,776)</u>	-	-	<u>(3,899)</u>	<u>(11,675)</u>
Income and expenditure account including pension reserve	<u>55,965</u>	<u>83,860</u>	<u>(80,529)</u>	<u>(7,450)</u>	<u>51,846</u>

14. Revaluation reserve

Group and Institute

	£000
<i>At 1 August 2009</i>	31,167
Unrealised deficit on revaluation of fixed assets	<u>(3,809)</u>
Revaluation reserve at 31 July 2010	<u>27,358</u>

THE INSTITUTE OF CANCER RESEARCH
NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 July 2010

15. Endowments

	Balance at 1 August 2009 £000	Income £000	Expend- iture £000	Transfers, gains and losses £000	Balance at 31 July 2010 £000
<i>Expendable endowments</i>					
FC Hunter Studentship Fund	569	-	-	-	569
Joan Francis Stowe Fund	14	-	-	-	14
Cancer Research UK Epidemiology Fund	<u>237</u>	<u>-</u>	<u>-</u>	<u>(237)</u>	<u>-</u>
Total expendable endowment funds	<u>820</u>	<u>-</u>	<u>-</u>	<u>(237)</u>	<u>583</u>
<i>Permanent endowments</i>					
Hensley Nankivell Studentship Fund	918	-	-	131	1,049
Sir SK Tang Fund	475	-	-	66	541
The Ivan and Felicite Stoller Fund	<u>311</u>	<u>-</u>	<u>-</u>	<u>43</u>	<u>354</u>
Total permanent endowment funds	<u>1,704</u>	<u>-</u>	<u>-</u>	<u>240</u>	<u>1,944</u>
Total endowment funds	<u>2,524</u>	<u>-</u>	<u>-</u>	<u>3</u>	<u>2,527</u>

The FC Hunter Studentship Fund is a legacy from the estate of Mr FC Hunter designated by The Institute for the purpose of supporting research studentships.

The Joan Frances Stowe Fund finances the Joan Frances Stowe Prizes in Palliative and Nursing Care.

The Cancer Research UK Epidemiology Fund represented the accumulated surplus on an endowment originally received from, and subsequently returned to, Cancer Research UK.

The Hensley Nankivell Studentship Fund was received from the estate of Mrs SMA Nankivell for the purpose of supporting research studentships at The Institute. The Sir SK Tang Fund (Endowment Fund) is a legacy received from the estate of Sir SK Tang. The Ivan and Felicite Stoller Fund is a legacy received from the estate of Mr IM Stoller. The income from both the Tang and Stoller funds is for cancer research.

16. Lease Commitments

At 31 July 2010 The Institute had annual operating lease commitments in respect of property leases which expire as follows:

	2010	2009
	£000	£000
Between two and five years	<u>465</u>	<u>465</u>

17. Capital commitments

	2010	2009
	£000	£000
Contracted but not provided for	3,061	1,067
Authorised by the Board of Trustees but not contracted for	<u>1,936</u>	<u>559</u>
	<u>4,997</u>	<u>1,626</u>

The capital commitments relate to laboratory and office building works and equipment.

18. Emoluments of the Board of Trustees

No fees are paid to the 24 members of the Board of Trustees for their services as charity trustees or company directors. There are six members of staff of The Institute who are members of the Board of Trustees who receive only the normal remuneration of their appointments. This includes the Chief Executive and Academic Dean whose remuneration is shown in note 18 (iii). The other four staff members, Professor Meier, Professor Pearson, Professor Springer and Professor Webb are the representatives elected by the Academic Board to serve on the Board of Trustees whose remuneration is included in note 18 (iv). In addition Miss Heinzmann was the student representative on the Board of Trustees who received the normal PhD student stipend. The aggregate emoluments of those who serve on the Board of Trustees was £820,182 (2009: £761,534). The emoluments of the highest paid director, who is a member of a multi-employer defined benefit pension scheme, were £222,000 (2009: £208,000). The six staff who are trustees participate in defined benefit pension schemes.

Five non-executive trustees received a total of £2,713 (2009: six received £3,963) for reimbursement of travel expenses.

19. Staff costs

(i) Average number of employees

	2010	2009
	No.	No.
Research Staff	854	836
Research support staff	139	137
Fundraising services	33	30
Corporate services including academic services	70	72
	<u>1,096</u>	<u>1,075</u>

(ii) Remuneration

	2010	2009
	£000	£000
Wages and salaries	42,387	40,404
Social security costs	3,290	3,069
Other pension costs	5,649	5,021
Pension past service cost	(5,044)	-
	<u>46,282</u>	<u>48,494</u>

The pension past service cost credit relates to the move from RPI to CPI on which index-linked pension increases are expected to be based in future.

(iii) Remuneration of Executive Directors

The remuneration of Executive Directors is listed below inclusive of distinction awards. National Insurance contributions and employer's pension contributions are excluded except where indicated.

	2010	2009
	£000	£000
Chief Executive	212	202
Academic Dean and Head of Clinical Laboratories	222	208
Secretary of The Institute	128	129
Chief Executive including employer's pension contributions	243	230

(iv) Remuneration of higher paid staff

	2010	2009
	No.	No.
£60,001 - £70,000	30	27
£70,001 - £80,000	9	10
£80,001 - £90,000	8	10
£90,001 - £100,000	8	7
£100,001 - £110,000	5	5
£110,001 - £120,000	4	1
£120,001 - £130,000	2	4
£130,001 - £140,000	3	3
£140,001 - £150,000	3	3
£150,001 - £160,000	2	2
£160,001 - £170,000	4	4
£170,001 - £180,000	4	2
£180,001 - £190,000	-	1
£200,001 - £210,000	1	2
£210,001 - £220,000	2	2
£220,001 - £230,000	1	-
£230,001 - £240,000	1	-

19. Staff costs (continued)

(v) Superannuation schemes

The Institute participates in three superannuation schemes. The majority of scientific and other non-clinical staff are in the Universities Superannuation Scheme (USS) (and the Universities Supplementary Dependants & Ill- Health Retirement Pension Scheme (USDPS)). The majority of clinical staff are in the National Health Service Superannuation Scheme (NHSPS). The ICR Pension Scheme (ICRPS) was closed to future accrual for new and existing members on 31 July 2008 and most of its active members joined the USS. All three schemes provide benefits based on final pensionable salary.

a) Universities Superannuation Scheme (USS) (and the Universities Supplementary Dependants & Ill Health Retirement Pension Scheme (USDPS))

This is a defined benefit scheme which is externally funded and contracted out of the State Second Pension Scheme (S2P). The assets of the scheme are held in a separate fund administered by the trustee, Universities Superannuation Scheme Limited. The appointment of directors to the board of the trustee is determined by the company's Articles of Association. Four of the directors are appointed by Universities UK; three are appointed by the University and College Union, of whom one at least must be a USS pensioner member; one is appointed by the Higher Education Funding Councils; and a minimum of two and a maximum of four are co-opted directors appointed by the board. Under the scheme trust deed and rules, the employer contribution rate is determined by the trustee, acting on actuarial advice.

Because of the mutual nature of the scheme, the scheme's assets are not hypothecated to individual institutions and a scheme wide contribution rate is set. The Institute is therefore exposed to actuarial risks associated with other institutions' employees and is unable to identify its share of the underlying assets and liabilities of the scheme on a consistent and reasonable basis and therefore, as required by FRS17 'Retirement benefits' accounts for the scheme as if it were a defined contribution scheme. As a result the amount charged to the Statement of Financial Activities represents the contributions payable to the scheme in respect of the accounting period.

The latest triennial valuation of the scheme was at 31 March 2008. This was the first valuation for USS under the new scheme-specific funding regime introduced by the Pensions Act 2004, which requires schemes to adopt a statutory funding objective, which is to have sufficient and appropriate assets to cover their technical provisions. The actuary also carries out a review of the funding level each year between triennial valuations and details his estimate of the funding level at 31 March 2010 are included in this note. The triennial valuation was carried out using the projected unit method. The assumptions which have the most significant effect on the result of the valuation are those relating to the rate of return on investments (i.e. the valuation rate of interest), the rates of increase in salary and pensions and the assumed rates of mortality. The financial assumptions were derived from market yields prevailing at the valuation date. An 'inflation risk premium' adjustment was also included by deducting 0.3% from the market-implied inflation on account of the historically high level of inflation implied by government bonds (particularly when compared to the Bank of England's target of 2% for CPI which corresponds broadly to 2.75% for RPI per annum). To calculate the technical provisions, it was assumed that the valuation rate of interest would be 6.4% per annum (which includes an additional assumed investment return over gilts of 2% per annum), salary increases would be 4.3% per annum (plus an additional allowance for increases in salaries due to age and promotion reflecting historic scheme experience, with a further cautionary reserve on top for past service liabilities) and pensions would increase by 3.3% per annum.

Standard mortality tables were used as follows:

Male members' mortality	PA92 MC YoB tables - rated down 1 year
Female members' mortality	PA92 MC YoB tables - no age rating

Use of these mortality tables reasonably reflects the actual USS experience but also provides an element of conservatism to allow for further small improvements in mortality rates. The assumed life expectations on retirement at age 65 are:

THE INSTITUTE OF CANCER RESEARCH**NOTES TO THE FINANCIAL STATEMENTS**for the year ended 31 July 2010

19. Staff costs (continued)

Males (females) currently aged 65	22.8 (24.8) years
Males (females) currently aged 45	24.0 (25.9) years

At the valuation date, the market value of the assets of the scheme was £28,842.6 million and the value of the scheme's technical provisions was £28,135.3 million indicating a surplus of £707.3 million. The assets therefore were sufficient to cover 103% of the benefits which had accrued to members after allowing for expected future increases in earnings.

The actuary also valued the Scheme on a number of other bases as at the valuation date. On the scheme's historic gilts basis, using a valuation rate of interest in respect of past service liabilities of 4.4% per annum (the expected return on gilts) the funding level was approximately 71%. Under the Pension Protection Fund regulations introduced by the Pensions Act 2004 the Scheme was 107% funded; on a buy-out basis (i.e. assuming the Scheme had discontinued on the valuation date) the assets would have been approximately 79% of the amount necessary to secure all the USS benefits with an insurance company; and using the FRS17 formula as if the USS was a single employer scheme, using an AA bond discount rate of 6.5% per annum based on spot yields, the actuary estimated that the funding level at 31 March 2008 was 104%.

The technical provisions relate essentially to the past service liabilities and funding levels, but it is also necessary to assess the ongoing cost of newly accruing benefits. The cost of future accrual was calculated using the same assumptions as those used to calculate the technical provisions except that the valuation rate of interest assumed asset outperformance over gilts of 1.7% per annum (compared to 2% per annum for the technical provisions) giving a discount rate of 6.1% per annum; also the allowance for promotional salary increases was not as high. There is currently uncertainty in the sector regarding pay growth. Analysis has shown very variable levels of growth over and above general pay increases in recent years, and the salary growth assumption built into the cost of future accrual is based on more stable, historic, salary experience. However, when calculating the past service liabilities of the scheme, a cautionary reserve has been included, in addition, on account of the variability mentioned above.

The scheme wide contribution rate required for future service benefits alone at the date of the valuation was 16% of pensionable salaries and the trustee company, on the advice of the actuary, agreed to increase the institution contribution rate to 16% on pensionable salaries from 1 October 2009.

Since 31 March 2008 global investment markets have continued to fluctuate and at 31 March 2010 the actuary has estimated that the funding level under the new scheme specific funding regime had fallen from 103% to 91% (a deficit of £3,065m). Compared to the previous 12 months, the funding level has improved from 74% (as at 31 March 2009) to 91%. This estimate is based on the funding level at 31 March 2008, adjusted to reflect the fund's actual investment performance over the two years and changes in market conditions (market conditions affect both the valuation rate of interest and also the inflation assumption which in turn impacts on the salary and pension increase assumptions).

On the FRS17 basis, using a AA bond discount rate of 5.6% per annum based on spot yields, the actuary estimated that the funding level at 31 March 2010 was 80%. An estimate of the funding level measured on a buy-out basis at that date was approximately 57%.

Surpluses or deficits which arise at future valuations may impact on The Institute's future contribution commitment. A deficit may require additional funding in the form of higher contribution requirements, where a surplus could, perhaps, be used to similarly reduce contribution requirements. The sensitivities regarding the principal assumptions used to measure the scheme liabilities on a technical provisions basis as at the date of the last triennial valuation are set out below:

19. Staff costs (continued)

Assumption	Change in assumption	Impact on scheme liabilities
Valuation rate of interest	Increase/decrease by 0.5%	Decrease/increase by £2.2bn
Rate of pension increases	Increase/decrease by 0.5%	Increase/decrease by £1.5bn
Rate of salary growth	Increase/decrease by 0.5%	Increase/decrease by £0.7bn
Rate of mortality	More prudent assumption (move to long cohort future improvements from the medium cohort adopted at the valuation)	Increase by £1.6bn

USS is a 'last man standing' scheme so that in the event of the insolvency of any of the participating employers in USS, the amount of any pension funding shortfall (which cannot be otherwise recovered) in respect of that employer will be spread across the remaining participant employers and reflected in the next actuarial valuation of the scheme.

The trustee believes that over the long term equity investment and investment in selected alternative asset classes will provide superior returns to other investment classes. The management structure and targets set are designed to give the fund a major exposure to equities through portfolios that are diversified both geographically and by sector. The trustee recognises that it would be possible to select investments producing income flows broadly similar to the estimated liability cash flows. However in order to meet the long term funding objective within a level of contributions that it considers the employers would be willing to make, the trustee needs to take on a degree of investment risk relative to the liabilities. This taking of investment risk seeks to target a greater return than the matching assets would provide whilst maintaining a prudent approach to meeting the fund's liabilities. Before deciding what degree of investment risk to take relative the liabilities, the trustee receives advice from its internal investment team, its investment consultant and the scheme actuary, and considers the views of the employers. The strong positive cash flow of the scheme means that it is not necessary to realise investments to meet liabilities. The trustee believes that this, together with the ongoing flow of new entrants into the scheme and the strength of the covenant of the employers enables it to take a long term view of its investments. Short term volatility of returns can be tolerated and need not feed through directly to the contribution rate although the trustee is mindful of the desirability of keeping the funding level on the scheme's technical provisions close to or above 100% thereby minimising the risk of the introduction of deficit contributions. The actuary has confirmed that the scheme's cash flow is likely to remain positive for the next ten years or more.

The next formal triennial actuarial valuation is due as at 31 March 2011. The contribution rate will be reviewed as part of each valuation and may be reviewed more frequently.

At 31 March 2010, USS had over 135,000 active members and The Institute had 804 active members participating in the scheme.

The total pension cost for The Institute was £4,566,000 (2009: £3,994,000). This includes £385,000 (2009: £341,000) of outstanding contributions at the balance sheet date. The contribution rate payable by The Institute was 16% of pensionable salaries.

b) National Health Service Pension Scheme (NHSPS)

This Scheme is an unfunded, defined benefit scheme that covers NHS employers, General Practices and other bodies, allowed under the direction of The Secretary of State, in England and Wales. As a consequence it is not possible for The Institute to identify its share of the underlying scheme liabilities.

The scheme is subject to a full valuation by the Government Actuary to assess the scheme's assets and liabilities to review the contribution rates. The last such valuation, which determined current contribution rates was undertaken as at 31 March 2004 and covered the period from 1 April 1999 to that date. On advice from the actuary the contribution may be varied from time to time to reflect changes in the scheme's liabilities.

THE INSTITUTE OF CANCER RESEARCH**NOTES TO THE FINANCIAL STATEMENTS**
for the year ended 31 July 2010

19. Staff costs (continued)

The conclusion from the 2004 valuation was that the Scheme had accumulated a notional deficit of £3.3 billion against the notional assets as at 31 March 2004. However, after taking into account the changes in the benefit and contribution structure effective from 1 April 2008, the Scheme actuary reported that employer contributions could continue at the existing rate of 14% of pensionable pay. Up to 31 March 2008, the vast majority of employees paid contributions at the rate of 6% of pensionable pay. From 1 April 2008, employees' contributions are on a tiered scale from 6% up to 8.5% of their pensionable pay depending on total earnings.

The Institute charges employer's pension costs contributions to operating expenses as and when they become due. The total employer contribution payable was £531,000 (2009: £500,000). There were £44,000 (2009: £49,000) of outstanding contributions at the balance sheet date.

c) ICR Pension Scheme (ICRPS)

This is a defined benefit scheme which is externally funded and contracted out of the State Second Pension Scheme (S2P). The assets of the scheme are held in a separate trustee-administered fund. On 31 July 2008, the ICRPS closed to future accrual.

The total charged to the Income and Expenditure Account under FRS 17 for the year amounts to a credit of £4,388,000 (2009: charge of £23,000). This is equal to the service credit of £5,043,000 (2009: service cost £30,000), (including a past service credit of £5,044,000 in respect of the move of assumptions from RPI to CPI (2009: past service cost £19,000 in respect of enhanced early retirement pensions)), plus the settlement gain of £154,000 (2009: £nil), less other finance cost of £809,000 (2009: -£7,000).

A full actuarial valuation was carried out at 31 March 2010 and updated to 31 July 2010 by a qualified independent actuary. The main assumptions used by the actuary were:

	At 31 July 2010 (% p.a.)	At 31 July 2009 (% p.a.)
Future salary increases	n/a	4.80%
Future 5% LPI pension increases	2.90%	3.30%
Future 2.5% LPI pension increases	2.50%	n/a
Discount rate	5.30%	6.10%
Retail Prices Index ('RPI')	3.40%	3.30%
Consumer Prices Index ('CPI')	2.90%	n/a
Revaluation in deferment	2.90%	3.30%
Assumed life expectancies on retirement at age 65 are:		
Retiring today		
Males	22.1	22.1
Females	24.1	25.0
Retiring in 20 years time		
Males	23.5	23.1
Females	25.7	25.9

The assumptions used by the actuary are best estimates chosen from a range of possible actuarial assumptions which, due to the timescale covered, may not necessarily be borne out in practice.

The fair value of the Scheme's assets, which are not intended to be realised in the short term and may be subject to significant change before they are realised, and the present value of the Scheme's liabilities, which are derived from cash flow projections over long periods and thus inherently uncertain, were:

THE INSTITUTE OF CANCER RESEARCH
NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 July 2010

19. Staff costs (continued)

	Long term rate of return expected		Fair value	
	At 31 July 2010 (% p.a.)	At 31 July 2009 (% p.a.)	At 31 July 2010 £000	At 31 July 2009 £000
	Equities and property	7.30%	7.30%	15,937
Fixed interest	4.30%	4.30%	3,962	11,040
Index linked gilts	4.30%	4.30%	20,891	20,708
Alternatives	7.30%	n/a	8,562	n/a
Insured annuities	5.30%	6.10%	967	1,120
Cash and other	0.50%	0.50%	4,405	774
Overall return on scheme assets	5.35%	5.48%		

The assumptions used in determining the overall expected rate of return of the assets of the Scheme have been set having regard to yields available on government bonds, corporate bonds, bank base rates and incorporating appropriate risk margins where appropriate.

None of the assets of the scheme are invested in The Institute's own financial instruments, and none of the assets are properties or other assets used by The Institute.

The amounts recognised in the balance sheet are as follows:

	At 31 July 2010 £000	At 31 July 2009 £000
Fair value of scheme assets	54,724	56,100
Present value of funded obligations	(66,399)	(63,876)
	(11,675)	(7,776)
Present value of unfunded obligation	-	-
Unrecognised past service cost	-	-
Deficit in the Scheme	(11,675)	(7,776)
Irrecoverable surplus	-	-
Deficit	(11,675)	(7,776)
Related deferred tax asset	-	-
Net liability	(11,675)	(7,776)
<i>Amounts in the balance sheet</i>		
Liabilities	(11,675)	(7,776)
Assets	-	-
Net liability	(11,675)	(7,776)

The amounts recognised in the Income and Expenditure Account are as follows:

	2010 £000	2009 £000
Service cost	1	11
Interest on obligation	3,732	3,927
Expected return on Scheme assets	(2,923)	(3,934)
Past service cost	(5,044)	19
Gains on curtailments and settlements	(154)	-
Total	(4,388)	23
Actual return on Scheme assets	4,101	(4,179)

THE INSTITUTE OF CANCER RESEARCH
NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 July 2010

19. Staff costs (continued)

Changes in the present value of the Scheme liabilities	2010	2009
	£000	£000
Liabilities at beginning of the year	63,876	62,541
Service cost (net of employee contributions)	1	11
Contributions by employees	-	3
Interest cost	3,732	3,927
Gains on curtailments and settlements	(154)	-
Actuarial losses/(gains)	9,532	(1,037)
Past service cost	(5,044)	19
Benefits paid	(5,544)	(1,588)
Liabilities at end of year	<u>66,399</u>	<u>63,876</u>

The reported scheme liabilities at 31 July 2010 include obligations under the Scheme Rules of £59,474,000 and constructive obligations of £6,925,000. The Institute has an established practice of providing discretionary increases to pensions in payment where no inflation-linking is provided for under the Scheme Rules. The constructive obligation, as required under FRS17, represents the liabilities arising from the granting of further discretionary increases in future years. The Board of Trustees of the Institute decides annually whether discretionary payments should be made.

Changes in the fair value of assets are as follows:

	2010	2009
	£000	£000
Fair value of Scheme assets at beginning of year	56,100	61,826
Expected return on Scheme assets	2,923	3,934
Actuarial gains/(losses)	1,178	(8,114)
Contributions by employer	67	39
Contributions by employees	-	3
Benefits paid	(5,544)	(1,588)
Fair value of scheme assets at end of year	<u>54,724</u>	<u>56,100</u>

Actuarial losses recognised in the Statement of Total Recognised Gains and Losses (STRGL):

	2010	2009
	£000	£000
Actuarial losses	<u>(8,354)</u>	<u>(7,077)</u>

The Scheme's current Schedule of Contributions requires The Institute to contribute £790,000 to the Scheme in the year commencing 1 August 2010 although this is under review as part of the Scheme Specific Funding valuation as at 31 March 2010.

THE INSTITUTE OF CANCER RESEARCH
NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 July 2010

19. Staff costs (continued)

Amounts for the current and previous four periods are as follows:

	At 31 July 2010 £000	At 31 July 2009 £000	At 31 July 2008 £000	At 31 July 2007 £000	At 31 July 2006 £000
Present value of Scheme liabilities	(66,399)	(63,876)	(62,541)	(64,289)	(55,481)
Scheme assets	54,724	56,101	61,826	51,768	45,741
Deficit	(11,675)	(7,775)	(715)	(12,521)	(9,740)
Experience adjustments on					
Scheme liabilities	637	(1,687)	(154)	627	321
As a percentage of Scheme liabilities	1%	-3%	0%	1%	1%
Experience adjustments on					
Scheme assets	1,178	(8,114)	(3,545)	1,056	2,053
As a percentage of Scheme assets	2%	-14%	-6%	2%	4%
Cumulative actuarial losses shown in STRGL	(21,670)	(13,315)	(6,239)	(5,809)	(2,904)

The asset values reported above are bid values, with the exception of the figures as at 31 July 2007 and 31 July 2006 which are the mid-values as disclosed at prior year ends.

d) Unfunded pensions

A small group of pensioners, who retired under the previous superannuation scheme are in receipt of unfunded pensions paid directly by The Institute. These pensions are increased, at The Institute's discretion, by analogy, with the Pensions Act 1995.

(vi) Health and Safety at Work

The Institute through its Safety Committee performs its duties as an employing authority under the provisions of The Health and Safety at Work Act 1974.

20. Value Added Tax

The Institute incurred irrecoverable VAT amounting to some £1.6 million during the year (2009: £1.8 million). It is a member of the Charities Tax Reform Group which campaigns on behalf of its members for a reduction in their VAT burden.

21. Subsidiary undertakings

The Institute has the following subsidiary undertakings:

(i) ICR Chelsea Development Limited - The Institute owns 100% of the issued share capital of this company which has been set up to act as the developer of a refurbishment project which has now been completed. It did not make a profit or a loss for the periods ended 31 July 2010 and 31 July 2009, and its net assets at those dates amounted to £2. The accounts of ICR Chelsea Development Ltd have been consolidated into the accounts of The Institute.

(ii) ICR Sutton Developments Limited - The Institute owns 100% of the issued share capital of this company which has been set up to act as the developer of Institute properties. It made a profit of £12,330 for the year ended 31 July 2010 (2009: £12,687) which will be paid to The Institute by means of a payment under gift aid. Its net assets at 31 July 2010 and 31 July 2009 amounted to £2. The accounts of ICR Sutton Developments Ltd have been consolidated into the accounts of The Institute.

(iii) ICR Enterprises Limited - The Institute owns 100% of the issued share capital of this company which undertakes trading activities for the benefit of The Institute that The Institute cannot carry out itself as an exempt charity. It made a profit of £64,699 for the year ended 31 July 2010 (2009: £213,110) which will be paid to The Institute by means of a payment under gift aid. Its net assets at 31 July 2010 and 31 July 2009 amounted to £2. The accounts of ICR Enterprises Ltd have been consolidated into the accounts of The Institute.

THE INSTITUTE OF CANCER RESEARCH**NOTES TO THE FINANCIAL STATEMENTS**
for the year ended 31 July 2010

21. Subsidiary undertakings (continued)

(iv) ICR Equipment Leasing No.8 Limited - The Institute owns 100% of the share capital of this company which holds a leasehold interest in the Chester Beatty Laboratory. It made a profit of £103 for the year ended 31 July 2010 (2009: £154) which will be paid to The Institute by means of a payment under gift aid. Its net assets at 31 July 2010 and 31 July 2009 were £5,063. The accounts of ICR Equipment Leasing No.8 Limited have been consolidated into the accounts of The Institute.

(v) Everyman Action Against Male Cancer - The company is limited by guarantee and was dormant throughout the period ended 31 July 2010.

(vii) Other investments - The Institute is a founder and shareholder of four companies whose aims are to exploit the intellectual property generated at The Institute. The companies and The Institute's shareholding are Gamma Technologies Ltd (10%), PETRRA Limited (7.7%), PROACTA Inc (0.5%), Domainex Limited (3%) and Chroma Therapeutics Limited (0.2%). The cost of The Institute's shareholding of these companies is included in unlisted investments.

A summary of the results of the subsidiaries is set out below:

ICR Enterprises Limited

	2010	2009
	£000	£000
Turnover	132	533
Expenditure	(67)	(322)
Operating profit	65	211
Interest income	-	2
Payment under gift aid to The Institute	(65)	(213)
Profit for the year	-	-
Assets	222	329
Liabilities	(222)	(329)
Funds	-	-

ICR Equipment Leasing No. 8 Limited

	2010	2009
	£000	£000
Turnover	-	-
Expenditure	-	-
Operating profit	-	-
Payment under gift aid to The Institute	-	-
Profit for the year	-	-
Assets	5	5
Liabilities	-	-
Funds	5	5

21. Subsidiary undertakings (continued)

Development companies		
ICR Sutton Developments Limited and ICR Chelsea Development Limited		
	2010	2009
	£000	£000
Turnover	594	4,293
Expenditure	(582)	(4,280)
Operating profit	12	13
Payment under gift aid to The Institute	(12)	(13)
Profit for the year	-	-
Assets	242	522
Liabilities	(242)	(522)
Funds	-	-

22. Taxation

The Institute is an exempt charity within the meaning of Schedule 2 of the Charities Act 1993 and as such is a charity within the meaning of section 506 (1) of the Income and Corporation Taxes Act (ICTA) 1988. Accordingly The Institute is exempt from taxation in respect of income or capital gains received within categories covered by Section 505 of the ICTA 1988 or Section 256 of the Taxation of Chargeable Gains Act 1992 to the extent that such income or gains are applied to exclusively charitable purposes.

23. Indemnity insurance

The Institute has purchased indemnity insurance to provide the Board of Trustees and Officers with an indemnity against a wide range of legal actions which they might face in carrying out their duties. The cost of this insurance was £5,237 (2009: £5,237).

24. Related parties

The Institute has taken the exemption given by Financial Reporting Standard 8, Related Party Disclosures, from disclosing transactions with subsidiaries. There are no other related party transactions.

Goals

We have two strategic goals, which represent the priorities for our cancer research and through which we are able to fulfil our Mission.

Goal 1

To continue to be one of the best cancer research centres in the world.

Research

The Institute of Cancer Research is one of the world's leading cancer research organisations and is internationally renowned for the quality of its science. Together with The Royal Marsden NHS Foundation Trust it also forms an internationally recognised top ranking Comprehensive Cancer Centre. Our integrated work in genetics, molecular biology and drug development is unrivalled in the world and provides the opportunity for ICR scientists to transform the prospects for cancer patients. Our first goal demonstrates our intention to continue to undertake and be recognised for research at the highest international level.

Goal 2

To continue to make a major contribution to the education and training of the next generation of leaders in cancer research.

Education

Given the concentration of world class scientific and clinical expertise within our organisation, we believe we have the enthusiasm, skills and motivation to ensure that all our students, postdoctoral staff, scientists and clinicians receive the best education and training to develop their talent and launch them into a successful career in cancer research and clinical practice.

Strategic Objectives

Our goals are underpinned by a series of objectives, which focus our attention on the practical way in which we will achieve them. In addition, we recognise the need to make sure we have both sufficient resources and the organisational capacity to deliver them.

Goal 1

To continue to be one of the best cancer research centres in the world.

Objective 1

To enact excellent basic, translational and clinical research throughout the ICR as defined by international peer review.

Objective 2

To achieve success in the three major strands of the scientific strategy as defined by the outputs in genetic epidemiology, molecular pathology and therapeutic development.

Objective 3

Together with The Royal Marsden NHS Foundation Trust to continue to be an internationally recognised top ranking Comprehensive Cancer Centre so that the results of our research translate into long term patient benefit.

How will we measure success?

- *Through our long term achievements*
- *Through scientific peer review e.g.*
 - *achieving ratings which are 'world-leading' and 'internationally excellent' from HEFCE/RAE*
 - *achieving Cancer Research UK site visit ratings of 'Outstanding' or 'Forefront' or the equivalent rating from other funding bodies*
 - *review by the external Scientific Advisory Committee*
- *Through monitoring our grant application success rates*
- *Through monitoring the number of citations of our scientific papers.*

Cancer research, by the very nature of the disease, is a long term and complex undertaking. The timescale for a laboratory discovery to be translated into a proven and established patient benefit has, in the past, been over a decade. We therefore should be judged against our long term achievements and the surrogate measures of peer review. Both show the ICR to have made an enormous contribution to many of the significant advances in cancer treatment for a wide range of cancers and to have made a profound impact on cancer research throughout the world.

Peer Review Achievements

- In the 2008 Higher Education Funding Councils' Research Assessment Exercise the ICR had the highest percentage of research assessed as four stars, world leading, in the areas of biological sciences and cancer studies. We came top of the Times Higher Education overall table of HEIs that submitted to more than one UoA - ranking us as the UK's leading academic research centre, with 37% of activity ranked 4* (world leading) and 42% ranked 3* (internationally excellent); none of the ICR's research was ranked as 1* (nationally recognised)
- Since 2005, 26 major programmes of research at the ICR have been renewed for a further five years, following international peer-review and, in many cases, site visits. Over 80% of these were judged to be either 'Outstanding' or 'Forefront'¹ – the highest possible ratings
- 78.7% of all grant applications have been successful (by value) in the period from 2005 to 2009; 70.4% by number
- The Evidence Ltd UK Higher Education Research Yearbook for 2009 shows that we led all UK Higher Education Institutions in the impact of our research papers on biomedical science between 2004–2008 and that our papers have an impact that is more than twice the world average.

¹ A rating of 'Outstanding' implies that the research performed in the preceding period, or that planned for the forthcoming period, is of the highest international calibre, pioneering and trendsetting. A rating of 'Forefront' implies that the research is of international importance and will have substantial impact (Cancer Research UK definitions).

Long Term Achievements

The breadth and excellence of the ICR's work is demonstrated by its exceptional record of successes. These include:

- The dramatic discovery that the basic cause of cancer is damage to DNA
- The identification of the potential link between smoking and lung cancer which was subsequently confirmed
- The elucidation of the mechanism by which *RAS*, one of the most commonly activated genes in cancer, turns normal cells into tumour cells
- The isolation of the breast cancer gene, *BRCA2*, which enabled families with a history of the disease to be assessed for future risk, and laid the groundwork for the development of novel forms of therapy for *BRCA*-associated cancers
- The characterisation of the cancer gene, *BRAF*, leading to an accelerated drug discovery programme for the treatment of malignant melanoma and other tumours
- The synthesis of Busulfan, Chlorambucil and Melphalan and the development of Carboplatin, important anti-cancer drugs that are used worldwide
- Discovery of on average two drug development candidates per year over the last five years; an achievement unmatched anywhere in the world
- Making major contributions to modern high precision radiotherapy techniques, improving cancer control and reducing risk of toxicity
- The licencing of three novel series of anti cancer drugs to major pharmaceutical companies in the last three years; HSP90 inhibitor to Novartis, PKB inhibitor to AstraZeneca and PI3Kinase inhibitors to Genentech
- Consistently being the most effective Higher Education Institution (HEI) in the UK in terms of the impact on our scientific peers of our published work in biomedical sciences.

Major Achievements 2009/10

- We performed the first Phase I trial of an oral PARP inhibitor, Olaparib, in patients with cancer. We demonstrated that this treatment is safe and well tolerated, and in a focussed expansion we were the first to show significant activity for this treatment in patients with recurrent BRCA associated ovarian cancer. These trials are the first successful examples of personalised medicine using a synthetic lethality approach that targets a patient's tumour specific molecular defect
- Genome-wide association studies identified three genetic variants that increase the risk of developing acute lymphoblastic leukaemia (ALL), the most common cancer in children. These results are the first evidence that genetic makeup plays a major role in the risk of ALL and will provide insight into how the disease develops
- Genome-wide association studies have provided insight into the development of brain tumours identifying five genetic variants that can increase the risk of developing Glioma, the most common form of brain cancer
- We have described how Rho GTPases, a key group of proteins, involved in the spread of tumours, are activated. Three-dimensional structural analysis revealed the mechanism through which members of the DOCK family activate Rho GTPases. The results provide a basis for the development of drugs that can target DOCK proteins and block metastasis
- By applying innovative computer modelling to studies of cell movement, ICR researchers have for the first time been able to investigate the timing and duration of key cell-to-cell signalling processes. This approach will be important in understanding how different cell populations communicate with each other during cancer development and progression
- Studies on drugs used to treat Melanoma showed that targeting the BRAF protein should only be undertaken in patients with a faulty version of BRAF. These results underline the importance of personalising treatment to those who are likely to best benefit from BRAF-selective inhibitors

- We have discovered that having too many copies of the *FGFR1* gene can cause resistance to the widely used drug Tamoxifen and other hormone-based therapy in breast cancer. By identifying the importance of the *FGFR1* gene, these findings have revealed a new drug target for treating breast cancer in patients who would otherwise have a poor outcome
- The Cancer Research UK Centre for Cancer Therapeutics has developed GDC-0941 – a new drug which inhibits the PI3 kinase pathway – that reduces the most common form of brain tumour by 98% in laboratory tests. As a result, Phase I clinical trials are now being conducted in the UK and USA
- We have found that in bowel cancer cells carrying the inherited mutation of either *MLH1* or *MSH2* genes (which prevent cells from repairing damaged DNA), blocking the action of another type of DNA repair protein stops the cells repairing DNA damage. Targeting cells already carrying one of these mutations with a drug that blocks this second part of DNA repair could be an effective personalised treatment for bowel cancers caused by these mutations
- Results from clinical trials in early breast cancer have found that the effectiveness and patient-reported chronic side-effects of radiotherapy, are not any worse when given as a lower total dose, delivered in fewer, larger treatments compared with the standard of a higher total dose delivered over a longer time. As a result, radiotherapy treatments can be changed so that women spend less time in hospital and the cost to the NHS is reduced.

Objective 4

To ensure that those outputs of our research that can be commercially exploited are developed for maximum long term patient benefit.

How will we measure success?

- *Through the Board of Trustees reviewing our commercial activities to confirm they are maximising patient benefit*
- *Through the financial achievements in industrial and licensing income, the number of industrial collaborations and the number of patents filed.*

The ICR's discoveries are developed firstly for patient benefit and secondly for a fair financial reward. If a discovery could be used widely without further development then it should be made available through non-exclusive licensing; discoveries that require further development need to be progressed with an industrial partner.

Achievements 2009/10

- In 2008 the ICR's novel drug BGC945, which was developed to target ovarian cancer, was licensed to the company Onyx Inc. This drug is now in a Phase I clinical trial
- ICR began collaborations in 2009 with AstraZeneca and separately with MerckSerono in both cases to develop drugs against novel cancer targets
- The prostate cancer drug Abiraterone, which was invented by the ICR, has been showing great promise in the clinic and is now in late stage development by Cougar Inc. Cougar was recently acquired by Johnson & Johnson
- The novel Hsp90 inhibitor developed by ICR in collaboration with Vernalis is now in Phase II clinical trials. These trials are being conducted by Novartis who licensed this project from Vernalis. Hsp90 is involved in supporting the growth of cancer cells
- The ICR is collaborating with the company Biotronics3D to develop novel imaging technologies
- In 2010 the ICR was awarded a Seeding Drug Discovery Initiative award from the Wellcome Trust to develop drugs against a novel breast cancer target. This is the third drug discovery award that the ICR has received from the Wellcome Trust
- Other industrial collaborations that are ongoing at the ICR include those with GE Healthcare, GSK, Dexela, Zonare, Kudos, Siemens, Genentech, and Merck.

Goal 2

To continue to make a major contribution to the education and training of the next generation of leaders of cancer research.

Objective 5

To educate and train the next generation of cancer researchers.

How will we measure success?

- *Through consistently achieving a 100% pass rate for PhD submissions*
- *Through achieving at least 70% of PhD submissions within four years, and at least 90% completion rate within 7 years over a rolling 3 year period*
- *Through registering at least 100 students annually on the MSc Course(s)*

Achievements 2009/10

- In the past year all of our PhD submissions have been successful
- The target of 70% PhD submissions within four years was met
- The first cohort of taught course students successfully graduated from the MSc (Oncology) course
- The Quality Assurance Agency signed off as complete the ICR's actions in response to the recommendations of its 2008 Audit, confirming all necessary measures had been taken
- Student data management systems were designed and implemented
- The first Periodic Review of the MSc (Oncology) has been undertaken.

In order to achieve our goals we also need to ensure that the ICR has both the money and the organisational capacity to support them.

STRATEGIC PLAN 2010- 2015

Objective 6

To deliver a sustainable environment which maximises the ability of people to achieve their research potential both in the laboratory and the clinic.

How will we measure success?

- *Through an annual review of our research Team Leaders (both Career Faculty and Career Development Faculty)*
- *Through undertaking a triennial staff survey*
- *Through development and introduction of a Carbon Reduction Plan.*

Achievements 2009/10

- The triennial staff attitude survey was completed in late 2008. The findings suggest that positive views of life at the ICR have to a large extent been maintained over the last three years, with further progress being made in some areas since 2005
- As part of our ongoing commitment to sustainability we have achieved the Bronze Eco Campus Award.

Objective 7

To obtain sufficient funds to ensure the long term financial viability of the ICR's work.

How will we measure success?

- *Through adhering to the ICR's reserves policy throughout the year planning period, to maintain a target level of reserves of £19.3 million which may vary within the range of £17.4 million to £21.2 million depending on market conditions*
- *Through increasing the level of fundraising and legacy income to a level of £15 million per annum by 2020.*

Achievements 2009/10

- The reserves are currently forecast to be above or at the target level throughout and at the end of the planning period
- Since the Will for Free Scheme was launched in January 2003 we have received legacy pledges estimated to be worth over £56 million.

Objective 8

To remain an employer of choice.

How will we measure success?

- *Through achieving vacancy rates of no more than 12% per annum*
- *Through having turnover rates that are no greater than the median of comparable organisations*
- *Through monitoring the numbers of our staff who take up opportunities for development and training.*

Achievements 2009/10

- Annual vacancy rate to December 2009 was 10.1%
- Turnover was 10% in 2009 below the median of comparable organisations of 16%
- Continued expansion of the range of training and development activities for students and scientists
- 142 training programmes were held covering 1500 staff attendances to December 2009.

Objective 9

To deliver value for money.

How will we measure success?

- *Through the proportion of expenditure applied for charitable purposes being above the average of major cancer charities.*

Achievements 2009/10

The ICR's charitable expenditure in 2009 was 95% of total expenditure.

Objective 10

To have the flexibility to accommodate new research.

How will we measure success?

- *By ensuring we have the resources and ability to respond to Joint Research Committee initiatives.*

Achievements 2009/10

- The continued refurbishment of our laboratories in Chelsea using monies from SRIF 3. The refurbishment of the second floor of the CBO was completed in December 2008 and the refurbishment of the first and third floors were completed in June 2009
- Our IT network and data storage capability have been further upgraded
- Further investments in informatics systems have been made.

Objective 11

To deliver a high quality service.

How will we measure success?

- *Through achieving a user satisfaction survey score of 4 (good) or better on a scale of 1 (poor) to 5 (excellent) across all support services*
- *Through achieving 90% of our Service Level Agreements during the year by delivering services to the agreed standard or higher*
- *Through obtaining quality management accreditation where appropriate e.g. ISO9001.*

Achievements 2009/10

- The Faculty Survey of Corporate Services reflected a score of 3.7 out of 5 in 2008
- The aggregate of all Corporate Service SLA's consistently exceeded 100%
- Maintained OHSAS 18001:1999 occupational health and safety standard accreditation
- Maintained 9001:2000 accreditation for facilities management services
- Fall-over systems and network links have been further developed to provide enhanced IT system availability
- Improvements have been made to ensure the ICR's vulnerability to viruses and other 'malware' is actively managed and maintained at a low level.

Strategic Direction

Scientific Strategy

The Joint Research Committee determines our scientific strategy. It includes representation from both The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

The core of our strategy is the exploitation of the genetic information arising from many sources, but particularly from the Cancer Genome Project (CGP) that was made possible by the determination of the sequence of the human genome in 2001.

The CGP, devised by ICR scientists and carried out at the Wellcome Trust Sanger Institute, will produce a detailed molecular pathology of common tumour types. The challenge is to understand the biological significance of the information. Our partnership with The Royal Marsden NHS Foundation Trust creates one of the world's leading cancer research centres and enhances our ability to translate that information into patient benefit.

We will continue to focus on three main themes:

- Genetic epidemiology: We are seeking to understand how genes interact with lifestyle and environmental factors to cause cancer, contributing to our aim of discovering the causes of cancer and how to prevent it
- Molecular pathology: We are continuing to unravel the molecular basis of cancer to enable the development of better ways both to diagnose and stage the disease and to predict responses to treatment, contributing to our aim of improving cancer diagnosis and treatment
- Therapeutic development: We are focusing primarily on discovering new drug targets and developing drugs that precisely attack the molecular abnormalities which drive cancer, contributing to our aim of improving cancer therapies to save more lives. We also develop new ways of delivering radiotherapy.

All this will be underpinned by our excellent basic research increasing our knowledge of cell growth, function and mutation, and benefits from our nationally recognised clinical trials operation and the non-invasive monitoring of tumour response using our pioneering imaging expertise.

We will concentrate on researching those cancers where we can most swiftly translate our discoveries into patient benefit. These cancers are those where we have particular research expertise and The Royal Marsden NHS Foundation Trust has significant clinical practice: currently breast cancer through the Breakthrough Breast Cancer Research Centre, prostate cancer through our Male Urological Cancer Research Centre (underpinned financially through our Everyman campaign), haematological and paediatric cancers.

STRATEGIC PLAN 2010- 2015

Following the development of our new Scientific Strategy in 2010 we will also revise our strategic plan in order to ensure we have the correct infrastructure and resources to deliver it.

Learning, Teaching and Assessment Strategy

The second arm of our Mission is to train the next generation of cancer researchers and clinicians. The ICR is a College of the University of London. It offers postgraduate courses only. This reflects its status as a specialist cancer research organisation, working at the forefront of cancer research, and is integral to its strategic approach to learning, teaching and assessment. It has long-established provision for MPhil / PhD and MD(Res) students, and has recently also offered an MSc in Oncology, the first cadre of students who graduated in 2009. We will develop and enhance our research degrees programme through continuous improvement of our systems for recruitment, student and staff training; effective appraisal, and through acquiring and acting upon student feedback.

The addition of the taught postgraduate provision in Oncology provides valuable additions to the ICR's overall educational environment. We will exploit this where possible, especially in relation to the possible teaching of research methodology and thesis preparation, for the benefit of research degree students, and NIHR Academic Clinical Fellows. We are introducing a new assessment policy based on principles of fairness, relevance, and quality, and will be developing new procedures to underpin this policy.

We aim to provide excellent teaching and learning opportunities. Our split site and day-release students make e-learning central to this. We will finalise and implement an e-learning strategy designed to ensure we exploit its potential to the maximum and that students have the necessary resources and support to benefit from it. We will provide e-delivery of all mandatory core training for students and staff; gain feedback on our two current educational websites; explore the development of further relevant e-learning materials within the cancer science field, and continue to develop Cancer.ed (the ICR's Virtual Learning Environment). We will augment our e-learning provision with face-to-face training for research students, building on the basic skills and knowledge provided by the on-line material. For taught course students we will continue to develop the VLE to help develop social and academic interactions, and to enable students to acquire factual knowledge off-site so freeing their on-site days for interactive, discursive sessions.

Our relationship with The Royal Marsden NHS Foundation Trust is key to all the ICR's activities. The ICR and the Trust work together de facto as a specialist academic health sciences centre. We will continue to jointly support the development of the next generation of academic clinical consultants and researchers, in particular through shared responsibility for delivering the NIHR Academic clinical trainee schemes attached to the joint Biomedical Research Centre.

STRATEGIC PLAN 2010- 2015

The ICR has a long history of encouraging staff and student volunteering, community interaction and the communication of science. We remain committed to working to promote both the public understanding of science in general and of the work of the ICR in particular. We will seek to encourage young people into science, technology, engineering and maths (STEM) higher education courses and careers. We will identify and promote relevant volunteering opportunities for our staff.

Research Excellence

In order to strengthen our capacity for research of the highest quality, we engaged in a major recruitment campaign over the past few years, which led to 21 new members of the Faculty joining the ICR in the period 2006-2008.

In December 2008 the ICR's research excellence was confirmed by the outcome of the Higher Education Funding Council's Research Assessment Exercise. The ICR received the highest percentage of research assessed as four stars, world leading, in the areas of biological sciences and cancer studies and came top of the Times Higher Education overall table of HEIs that submitted to more than one UoA – ranking it as the UK's leading academic research centre.

The outstanding contribution made by our scientists to cancer research is recognised by the election of six of our Faculty to The Royal Society. Election to its Fellowship is the highest accolade that can be bestowed on a British Scientist.

In 2009 Professor Ashworth was awarded the Lifetime Achievement Award of the European Society for Medical Oncology in recognition of his pioneering work and Richard Marais, Professor of Molecular Oncology, was elected to Membership of the European Molecular Biology Organisation.

In April 2008, nine scientists from the ICR and The Royal Marsden NHS Foundation Trust were appointed to be Senior Investigators at The National Institute for Health Research. They join ninety one other top researchers from across the country who are considered to be outstanding leaders in the field of patient research. In April 2009 a further two scientists from the ICR and the Royal Marsden NHS Foundation Trust were appointed to this role.

Our staff have always been our greatest asset. Our record of achievement proves they have made a difference to cancer research in the past. Our current staff's expertise and calibre, together with the international recognition of our Faculty, give us every confidence they will continue to do so.

Financial Sustainability

In partnership, the ICR and The Royal Marsden NHS Foundation Trust, form an internationally recognised top ranking Comprehensive Cancer Centre with over 3,600 scientists, clinicians and nurses and an annual budget of £280 million.

The ICR has more than 1000 staff and postgraduate students. Its financial base is secure, net assets exceed £138 million, annual expenditure is over £86 million and free reserves, which are calculated on the basis of risk, are forecast to be at the target level of £19.3 million in 2015.

In 2010/11 our HEFCE funding will fall to some £18.5 million as moderation funding of £2 million provided in 2009/10 is withdrawn.

To sustain our financial position we must raise more money and reduce our cost base during 2010/11.

Our current funding is broadly HEFCE 31%, Cancer Research UK 26%, Breakthrough Breast Cancer 8%, Other Grants 22%, Investment and Overhead Income 5%, Fundraising 8%.

To safeguard our position and to provide for our sustainable expansion we aim to increase our fundraising income to £15 million per annum by 2020, mainly through our long term legacy fundraising, major gifts and trusts and our 'Everyman' action against male cancers campaign. We aim to be raising £10.4 million per annum by 2014/15.

We will continue to exploit our intellectual property, promoting interactions with the business community which ensure that our laboratory discoveries are developed for the benefit of patients and generate a significant income for reinvestment in the ICR's research. Our target is that by 2011 we will be generating in excess of £950k per annum from invention income and £1.7 million per annum from industrial collaborations and in excess of £700k of overheads on industrial collaborations.

These long term fundraising and commercialisation targets are ambitious; the income budgets, on which we base the expenditure plans, are more prudent.

Supporting Research

More than 90% of our laboratory estate has been built anew or refurbished over the last ten years at a cost of over £75 million. Following the opening of the Brookes Lawley Building in 2003 by Her Royal Highness, The Princess Royal, Chancellor of the University of London, we used the £9.2 million from the Science Research Investment Fund (SRIF 2) to complete, in 2005, the construction of the Sir Richard Doll Building at a cost of about £10 million. This liberated laboratory space in the Brookes Lawley Building.

Our allocation from SRIF 3 was £10.3 million. We have used this to complete the refurbishment of our McElwain and Hadow laboratories at Sutton and to refurbish the Chester Beatty old laboratory building in Chelsea.

This refurbished space will accommodate some of our new research initiatives in genetic epidemiology, haemato-oncology, molecular pathology, imaging, cancer therapeutics, paediatric oncology, cancer genetics, breast and prostate cancer, and cell, molecular and structural biology.

Our Capital allocations for 2008-11 comprised £17.2 million for the Research Capital Investment Fund and £139k for the Learning and Teaching Capital Investment Fund. The research capital funds will be used to continue to develop new facilities within our laboratories. In particular we have designed the second phase of the Sir Richard Doll Building in Sutton which will provide additional laboratory accommodation and allow us to establish a multi-modality imaging centre. The teaching capital funds have been used to fit out new facilities in Chelsea to accommodate the MSc in Oncology Course vacating space in the Chester Beatty Laboratories which has been converted to provide further laboratory accommodation.

We previously reported that the ICR and The Royal Marsden NHS Foundation Trust have been designated a National Institute for Health Research (NIHR) Biomedical Research Centre, the only one specialising in cancer. As a result, we were granted £11.3 million for a new building to accommodate much of our work in pathology, which is a key feature of our overall strategy. £1.5 million has been received from the Wolfson Foundation. We are currently designing this building.

In IT, an ongoing investment programme has led to substantial improvements in networking capability, systems availability, data storage management, and flexible and mobile working. In addition, improvements have been made to back office systems, particularly in HR, Finance and Purchasing. We have integrated our administrative systems so that processes are made as efficient as possible, both for support staff and scientists by ensuring a single point of contact for researchers. Virtualization technology is being used to deliver scientific applications at reduced cost and this infrastructure is to be further developed. These new investments mean that scientists can take advantage of enhanced infrastructure capacity at lower cost and improved performance and deal with administrative matters in a more efficient way. As scientific research becomes increasingly dependent on information management, the ICR is committed to meeting the challenges and realising the benefits of Information Technology in the areas of high performance computing,

STRATEGIC PLAN 2010- 2015

large-scale data management, collaborative systems, information storage and retrieval, and communications.

As part of our commitment to sustainable development we will take advantage of any funding streams to improve our environmental sustainability.

Continuous Improvement

The ICR has a programme of continuous improvement which includes benchmarking ourselves against the sector and undertaking regular process reviews of all our services.

Service Level Agreements have been implemented and reviewed for all Corporate Services that support the research and performance against these is regularly monitored. The ICR has maintained its OHSAS 18001:1999 Health & Safety accreditation and maintained ISO 9001:2000 accreditation for the Facilities Services. With regard to Investors in People, we will be submitting evidence to continue our accreditation in early 2011 and an external assessment will be part of this process.

We will develop an environmental management system as part of the Eco Campus Award Scheme.

Partnerships

Since we became a College of the University of London in September 2003, our involvement in University affairs has expanded. We participate in many activities seeking both research synergies and, for our infrastructure, economies of scale. Our other partnerships, with The Royal Marsden NHS Foundation Trust, our largest funders, Cancer Research UK, Breakthrough Breast Cancer and the Wellcome Trust, continue to prosper.

We collaborate with many other international and UK cancer charities and organisations in order to gain resources. We are most grateful to them all.

Future Plan to meet Strategic Objectives

There are a number of key areas that need the focus of our attention in the next few years.

Research

- To continue to make progress with the main themes of our current research strategy: genetic epidemiology, molecular pathology and therapeutic development
- To enact our new Scientific Strategy
- Continuous review of research priorities by the Joint Research Committee
- To pilot the Leadership Development Plan
- Reviewing the allocation of existing laboratory space to ensure that it is congruent with our Scientific Strategy
- Proactively working in partnership and collaboration with The Royal Marsden NHS Foundation Trust, Mount Vernon Cancer Centre, Cancer Research UK, Breakthrough Breast Cancer and other key organisations to fulfil our Mission
- Continuing to invest in IT to support scientific research, especially in relation to high performance computing and large scale data management.

Enterprise

- Ensuring effective exploitation of the ICR's intellectual property to optimise patient benefit.

Education

- Delivering the Learning, Teaching and Assessment Strategy 2009-12 according to the operating plan
- Providing the best possible learning environment for our students, research and corporate staff
- Continuing to ensure the successful completion of the ICR's students on the MSc in Oncology, and continuing to develop taught course provision.

Resources and Capacity

- Continuing to diversify our income from both research grants and our fundraising capacity
- Retaining the best staff to meet our needs
- Determine the process for succession planning for a number of our key scientific and managerial posts including that of the Chief Executive
- Ensuring our research is sustainable and further encouraging an integrated approach to infrastructure planning and investment
- Developing a plan to reduce our carbon emission and achieve the Gold Eco Campus Award
- Maintaining the new Health and Safety Strategy
- Managing risk
- Ensuring a scaleable IT infrastructure capable of supporting our new Research Strategy, exponential growth in data storage requirements and the allied need for data manipulation and processing.

The Board of Trustees

The Board of Trustees is the governing body of The Institute of Cancer Research and is constituted under Article 23 of the Institute's Articles of Association.

Name	Title/Nominating Body	No ¹ of meetings could have attended	No of meetings attended Aug 09 to July 10
Lord Ryder of Wensum OBE	Chairman/Co-option	12	12
Professor Sir Tom Blundell FRS FMedSci	Deputy Chairman & senior member/Co-option	12	9
Konstantin Graf von Schweinitz	Honorary Treasurer/Co-option	8	8
Professor P W J Rigby FRS FMedSci	Chief Executive/Ex Officio	6	6
Professor A Horwich PhD MRCP FRCP FMedSci	Academic Dean/Ex Officio	6	5
Miss R Bibby BSc(Hons) (to 9/2009) Miss K Heinzmann DipBiotech (from 10/2009)	Student	6	4
Mr A W C Edwards	Co-option	6	3
Mr D J Gleeson MA (to 6/2010)	Co-option	5	1
Dr P N Goodfellow FRS FMedSci	Co-option	8	5
Professor A L Harris DPhil FRCP FMedSci (from 1/2010)	Co-option	2	2
Mrs I Hotimsky MBA	Co-option	10	9
Mr H S Kumar MEng MBA	Cancer Research UK	6	4
Professor R A Laskey FRS FMedSci	University of London	10	7
Professor P Meier PhD	Academic Board	6	4
Lady Otton SRN (from 11/2009)	Co-option	5	4
Miss C A Palmer CBE MSc MHSM DipHSM Mrs T M Green CBE MA (to 10/2010)	The Royal Marsden NHS Foundation Trust Alternate Director	6	5
Mr J M Pearce	Co-option	6	6
Professor A Pearson MD FRCP FRCPCH DCH (from 2/2010)	Academic Board	3	3
Miss A C Pillman OBE	Co-option	6	6
Mr R S Sharp	Co-option	6	4
Professor C Springer PhD CChem FRSC	Academic Board	6	5
Miss M I Watson MA MBA FCIPD	Co-option	6	6
Professor S Webb PhD DIC DSc ARCS FInstP FIPEM FRSA CPhys CSci	Academic Board	6	6

¹Includes Board of Trustees, Constitutional and Nomination Committee and Remuneration Committee meetings

Senior members of staff in attendance at Board of Trustees meetings

Mr J M Kipling FCA DChA (to 12/2009) Mrs C Scivier MSc FCIPD MlOD (from 1/2010)	Secretary of the Institute and Head of Corporate Services
Professor C J Marshall FRS FMedSci	Director of Research/Chairman Joint Research Committee
Mr P F W Norris BSc(Hons) ACA MBA	Director of Finance
Mr S Surridge BSc(Hons) MRICS CDir FloD MBIFM	Director of Operations and Assistant Secretary

The Institute benefits from external expertise on the following committees that report to the Board of Trustees (as at 31 July 2010):

The Constitutional and Nomination Committee

Lord Ryder of Wensum OBE - *Chairman*
Professor Sir Tom Blundell FRS FMedSci – *Deputy Chairman*
Mrs I Hotimsky MBA
Professor R A Laskey FRS FMedSci

The Audit Committee

Mr J M Pearce – *Chairman*
Mr M J Usher BA CPFA – *Deputy Chairman*
Mr D R Fryatt MA FCA FCIBS
Mr S A Taylor MBA FCCA
Mr Pearce, Mr Fryatt and Mr Usher attended all 4 meetings held; Mr Taylor attended 3 meetings (August 2009 to July 2010)

The Remuneration Committee

Lord Ryder of Wensum OBE - *Chairman*
Professor Sir Tom Blundell FRS FMedSci – *Deputy Chairman*
Dr P N Goodfellow FRS FMedSci
Konstantin Graf von Schweinitz

The Investments and Building Development Committee

Konstantin Graf von Schweinitz - *Chairman*
Mr R J Elliott – *Deputy Chairman*
Mr K D Dew FRICS (*to 12/2009*)
Mr A Wolstenholme OBE BSc CEng FICE

The Institute also benefits from the expertise of those it has appointed as Trustees of The Institute of Cancer Research Pension Scheme (ICRPS)

Miss M I Watson MA MBA FCIPD – *Chairman*
Mr A W C Edwards
Mr R J Elliott
Konstantin Graf von Schweinitz

Academic Board (as at 31 July 2010)

The Academic Board advises the Board of Trustees upon all academic and teaching matters and questions of education policy.

Professor A Horwich PhD MRCP FRCP FMedSci *Chairman and Academic Dean*

Professor P W J Rigby FRS FMedSci *Chief Executive*

Professor A L Jackman PhD *Deputy Dean (Biomedical Sciences)*

Professor M Brada FRCP FRCP *Deputy Dean (Clinical Sciences)*

Dr J Bamber* PhD (*Senior Tutor – Sutton*)

Professor N M deSouza MD FRCP FRCP (*Senior Tutor – Clinical*)

Professor P Meier PhD (*Senior Tutor – CBL*)

Dr J Shipley* PhD (*Senior Tutor – Sutton*)

Dr V M Arlt PhD

Professor A Ashworth FRS FMedSci

Ms G Bachmann

Professor D Barford FRS FMedSci

Professor J Blagg DPhil CChem

Professor J Bliss MSc FRSS

Dr J Caldwell

Ms J Chang

Dr I Collins* PhD CChem FRSC

Professor C S Cooper DSc FMedSci

Professor D Cunningham MD FRCP

Professor The Lord Darzi of Denham KBE HonFREng FMedSci

Professor D Dearnaley MD FRCP FRCP

Dr J de Bono* MSc PhD FRCP

Ms S Dolan MSc RGN

Professor M Dowsett PhD

Dr S Eccles* PhD

Professor R Eeles PhD FRCP FRCP

Professor P Evans DPhil FInstP FIMA

Professor C Fisher MD DSc(Med) FRCPATH HonMRCP

Professor M E Gore PhD FRCP

Professor M Greaves PhD FRCPATH HonMRCP FRS FMedSci

Dr K Harrington* PhD FRCP FRCP

Mr A Hayes PhD FRCS

Professor R S Houlston MD PhD FRCP FRCPATH FMedSci

Dr R Huddart* PhD MRCP FRCP

Professor C Isacke DPhil

Professor S Johnston PhD FRCP

Professor K Jones PhD CChem FRSC

Professor I Judson MD FRCP

Dr M Katan* PhD

Professor S Kaye MD FRCP FRCP FRSE FMedSci

Dr V Khoo MD FRACP FRCP

Professor M O Leach PhD FInstP FIPEM CPhys FMedSci FSB

Professor R M Marais PhD FMedSci

Professor C J Marshall FRS FMedSci

Dr E Matutes* MD PhD FRCPATH

Professor S Mitnacht PhD

Professor G Morgan PhD FRCP FRCPATH

Professor P S Mortimer MD FRCP MRCS

Dr S Moss* PhD HonMFPH

Dr R Natrajan

Dr C Nutting* MD ECMO FRCP FRCP

Dr G Payne DPhil MInstP MIPEM

Professor A Pearson MD FRCP FRCPCH DCH

Professor D H Phillips PhD DSc FRCPATH

Professor N Rahman PhD FRCP FMedSci

Professor J Reis-Filho MD PhD FRCPATH

Professor I Smith MD FRCP FRCPE

Professor C J Springer PhD CChem FRSC

Professor G Stamp MB ChB MRCPATH

Professor A Swerdlow PhD DM DSc FSB FFPH FRCPG FMedSci

Dr J Taylor

Dr G ter Haar* DSc PhD FIPEM FAIUM
Dr G Thomas* MD MRCPI
Professor S Webb PhD DIC DSc ARCS FInstP FIPEM FRSA CPhys CSci
Professor K R Willison PhD
Professor P Workman PhD DSc(Hon) FSB FMedSci
Professor J Yarnold MRCP FRCR
Dr A Zelent* PhD
Dr M Zvelebil* PhD
*Reader

Fellows of the Institute

The honorary appointment of Fellow of the Institute is conferred upon distinguished individuals who have some connection with the Institute or with cancer research in its broadest sense. Such appointments are in recognition of past achievement and based on a major contribution to the advancement of the Institute's objectives.

Sir John Ashworth PhD DSc
Professor P Brookes PhD DSc
Professor Sir Kenneth Calman KCB FRSE
Professor D Catovsky MD DSc(Med) FRCPPath FRCP FMedSci
Mr E A C Cottrell
Dr M J Crumpton CBE PhD HonFRCPPath FRS FMedSci
Professor T M Dexter DSc HonFRCP FRS FMedSci
Lord Faringdon KCVO
Professor P B Garland CBE MA PhD LLD(hc) FRSE
Professor K R Harrap CBE DSc FRSC
Mr J M Kipling FCA DChA
Professor P D Lawley PhD DSc
Baroness Morgan of Drefelin
Professor Sir Michael Peckham MA MD FRCP FRCP(G) FRCR FRCPPath FRCS
Sir Kenneth Stowe GCB CVO MA HonDSc(Med)
Professor M Waterfield FRS FMedSci
Professor R A Weiss PhD HonFRCP FRCPPath FRS FMedSci
Professor G Westbury OBE MB BS FRCP FRCS HonFRCSEd

Members of the Institute

The Members of the Institute are persons who, by reason of their past and present contributions, are, in the opinion of the Board of Trustees, likely to assist the furtherance of the objects of the Institute. Members are subscribers to the Institute's Memorandum of Association and as such are entitled to attend the Institute's Annual General Meeting and any Extraordinary General Meeting which may be convened.

Mr N Ashley DUniv
Sir John Ashworth PhD DSc
Dr P J Bailey PhD
Lord Bell FIPA FIPPR FPRCA
Professor A J Bellingham CBE FRCP FRCPPath
Professor Sir Tom Blundell FRS FMedSci
Dr M Bodmer PhD
Sir Henry Boyd-Carpenter KCVO MA
Mrs E Brooks
Mr R Brooks HonLittD
Mr J M Cartwright FCA ATII
Mr E A C Cottrell
Miss P M Cunningham CBE
Professor G A Currie MD FRCP FRCPPath
Mr S R Davie CB
Professor A J S Davies PhD DSc
Mr M de Ferranti BSc
Mr J J Defries BCom IPFA
His Honour Judge Keith Devlin PhD
Mr K D Dew FRICS
Dr A Diment PhD
Mr A W C Edwards
Mr R J Elliott
Lord Faringdon KCVO
Mrs J M Firth CB PhD
Dr S E Foden DPhil

Professor A B Foster DSc
Mr B W Freedman
Mr D Fryatt MA FCA FCIBS
Professor P B Garland CBE MA PhD LLD(hc) FRSE
Mr D J Gleeson MA
Dr P N Goodfellow FRS FMedSci
Professor A Harris DPhil FRCP FMedSci
Dr T A Hince PhD
Mr J Hollond
Mrs I Hotimsky MBA
Mrs S A Johnson BA
Mr P J C Keemer MPhil
Mr J M Kipling FCA DChA
Mr K C Lawrance
Mr A E Lightly FRICS
Mr M G Lillywhite
Dr M J Morgan PhD
Professor H R Morris FRS
Mr R Mould
Professor G J Mufti DM FRCP FRCPATH
Professor S Neidle PhD DSc ARCS DIC FRSC
Professor A van Oosterom MD PhD
Professor R J Ott PhD FInstP CPhys HonFBIR
Lady Otton SRN
Mr J M Pearce
Professor Sir Michael Peckham MA MD FRCP FRCP(G) FRCR FRCPATH FRCS
Miss A C Pillman OBE
Mrs Tim Rathbone
Professor Dame Lesley Rees DBE MD DSc FRCP FRCPATH FMedSci
Mr G E Richardson FRICS
Dame Stella Rimington DCB
Lord Ryder of Wensum OBE
Mr G Sangster
Konstantin Graf von Schweinitz
Mr J Seymour
Mr R S Sharp
Dr K Snell PhD FRSA LRPS
Mr R E Spurgeon
Ms A Stevens MA DLitt(Hon)
Sir Kenneth Stowe GCB CVO MA HonDSc(Med)
Mr S A Taylor MBA FCCA
Mr M J Usher BA CPFA
Miss M I Watson MA MBA FCIPD
Professor G Westbury OBE MB BS FRCP FRCS HonFRCSEd
Sir David Innes Williams MA MD MChir FRCS
Mr A Wolstenholme OBE BSc CEng FICE
Mr D H Wootton

Associates of the Institute

Appointment as an Associate of the Institute is conferred on long-serving ex-employees of the Institute or on those former members of staff or students or other individuals who are deemed eligible by reason of their having rendered exceptional service to the Institute or having otherwise done something outstanding to enhance the reputation of the Institute.

Mrs R J Atkins
Ms M Barrell
Mr D A Brunning ALA
Professor R L Carter CBE MA DM DSc FRCP FRCPATH
Professor J Chamberlain MB FRCP FFPH
Mr N Clarke
Miss S Clinton
Mr P F Collins
Mrs J Cordell BSc(Hons) MPhil
Professor J L Corner PhD RGN OncCert
Dr A R Crathorn PhD
Dr D A Darcy MA DPhil
Mr A de Paiva
Mrs C A Faux
Dr E O Field DM DMRD
Dr M A Flower PhD FIPEM
Mr F Friedlos MPhil
Mrs P M Goddard MPhil
Dr G H Goodwin PhD
Mr J W Goodwin
Dr H S Greer MD FRCPsych FRANZCP
Mr L J Griggs BSc
Dr P L Grover DSc
Professor B A Gusterson PhD FRCPATH
Professor J G Hall PhD DSc MRCS LRCP FRCPATH
Mr J G Harris
Mr A J Hewer CBiol
Professor C R Hill DSc FInstP FIEE HonFRCR HonFIPEM
Professor M Jarman DSc CChem FRSC
Mr M Jones MIBiol
Dr H King PhD
Mrs M Kipling
Mrs B Lloyd
Mr R MacCormick
Mr K A Markham FRICS
Mrs R Marriott
Dr E McDonald MA PhD ARCS
Mr R K Merrifield MSc
Mr E Merryweather
Dr M Osborne PhD
Dr K Owusu-Ankomah BSc(Hons)
Mr G Parnell CBiol MIBiol MISTR
Dr J H Peacock PhD
Mrs R A Pendry FBIFM AMIBiol
Professor C R Pinkerton MD FRCPCH FRACP
Mr D J C Simmons MPhil FIBMS
Mrs M Snigorska
Professor G G Steel DSc
Mr A Stewart
Mrs S M Stockbridge
Professor D M Taylor DSc FRSC FRCPATH
Miss D L Tharp BSc
Mr J Thorne MA
Mr M Valeri BSc(Hons)
Dr S Venitt PhD
Mr W Warren BSc
Mr T West
Dr K Weston PhD

Legal and administrative information

Auditors

Crowe Clark Whitehill LLP
St Bride's House, 10 Salisbury Square, London EC4Y 8EH

Bankers

Coutts & Co
Chandos Branch, 440 Strand, London WC2R 0QS

HSBC plc
Onslow Square Branch, 1 Sydney Place, London SW7 3NW

Investment Managers

Partners Capital LLP
5 Young Street, London W8 5EH

Solicitors

Farrer & Co
66 Lincoln's Inn Fields, London WC2A 3LH

Registered Office

123 Old Brompton Road
London SW7 3RP

Company number

534147